<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fetal hemoglobin (Hb F) in health and disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fetal hemoglobin (Hb F) in health and disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fetal hemoglobin (Hb F) in health and disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin H Steinberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Swee Lay Thein, MD, FRCP, FRCPath, DSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford M Takemoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H359562777"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fetal hemoglobin (Hb F; alpha2gamma2) is the major hemoglobin in fetal red blood cells (RBCs) during gestation and constitutes 60 to 80 percent of total hemoglobin in the full-term newborn. By approximately 6 to 12 months of age, Hb F is almost completely replaced by adult hemoglobin (Hb A; alpha2beta2).</p><p>Regulation of Hb F and clinical implications of increased Hb F are discussed here. Other normal hemoglobins and RBC production are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a> and  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p class="headingAnchor" id="H359562785"><span class="h1">BIOLOGY OF Hb F</span></p><p class="headingAnchor" id="H1889612450"><span class="h2">Globin evolution and genomic organization</span><span class="headingEndMark"> — </span>Human Hb F arose from millennia of evolution of ancient hemoproteins by gene duplication, deletions, conversions, inactivations, mutations, and translocations to different chromosomes that resulted in altered regulatory control and globin function [<a href="#rid1">1,2</a>]. Functional hemoglobins are tetramers of two alpha and two non-alpha globin chains. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a>.)</p><p>Hb F evolved to potentiate the transfer of oxygen (O<sub>2</sub>) from maternal blood to fetal tissues, a goal achieved by the higher O<sub>2</sub> affinity of Hb F compared with adult Hb A. This is largely due to the insensitivity of Hb F to 2,3 BPG (sometimes called 2,3 DPG), the major modulator of hemoglobin-O<sub>2</sub> affinity. Modern human globin genes reside in two separate gene clusters  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alpha globin locus</strong><strong><em> </em></strong>– The alpha globin locus, near the telomere of the short arm of chromosome 16 (16p13.3), has three globin coding genes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two alpha globin genes (<em>HBA2 </em>and <em>HBA1) </em></p><p class="bulletIndent2"><span class="glyph">•</span>The embryonic alpha-like zeta globin gene (<em>HBZ)</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta globin locus</strong> – The beta globin locus, on the short arm of chromosome 11 (11p15.5), has five globin coding genes: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An embryonic epsilon globin gene (<em>HBE1</em>)</p><p class="bulletIndent2"><span class="glyph">•</span>Two gamma globin genes (<em>HBG2</em>, also called Gγ [G-gamma]<em> </em>and <em>HBG1, </em>also called Aγ [A-gamma];<em> </em>together referred to herein as<em> HBG</em>), expressed predominantly in the fetal liver and bone marrow and forming Hb F (alpha2gamma2)</p><p class="bulletIndent2"><span class="glyph">•</span>A delta globin gene (<em>HBD</em>), coding for the minor adult hemoglobin Hb A<sub>2</sub> (alpha2delta2)</p><p class="bulletIndent2"><span class="glyph">•</span>The beta globin gene (<em>HBB</em>), coding for the major adult hemoglobin Hb A (alpha2beta2)<em> </em></p><p></p><p class="bulletIndent1"><em>HBD</em> a<em>nd HBB</em> are expressed in adults.</p><p></p><p class="headingAnchor" id="H1394538374"><span class="h2">Gamma globin genes (<i>HBG2</i> and <i>HBG1</i>)</span><span class="headingEndMark"> — </span><em>HBG2</em> (Gy [G-gamma]) and <em>HBG1</em> (Ay [A-gamma]) are 5' (upstream) of <em>HBB</em>  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). (See <a class="local">'Globin evolution and genomic organization'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sequence</strong> – <em>HBG2</em> and <em>HBG1 </em>share same the intron-exon structure of all human globins, with identical exons except at position 136, where <em>HBG2</em> codes for glycine (G-gamma), while <em>HBG1</em> codes for alanine (A-gamma) [<a href="#rid3">3</a>]. Whether position 136 is alanine or glycine does not affect Hb F function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expression</strong> –<em> HBG2 </em>is expressed at higher values than <em>HBG1</em> during fetal development. After the switch from production of Hb F to Hb A, G-gamma globin falls from approximately 70 percent at birth to approximately 40 percent six months postnatally. The <em>HBG2</em> to <em>HBG1</em> switch does not occur in individuals with the Xmn1 G-gamma site in the <em>HBG2</em> promoter [<a href="#rid4">4</a>]. (See <a class="local">'HBG2 Xmn1 polymorphism'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>HBG </em></strong><strong>variants </strong>– The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fglobin.bx.psu.edu%2F&amp;token=8H3asYqReYgQFFdRgbitkCSQittb6XZHTeX0Dor5YDL1HrTB4H5KCvI%2F29D45586&amp;TOPIC_ID=90749" target="_blank">Globin Gene Server</a> reports &gt;140 variants affecting the structure or expression of the gamma globin genes (another resource is <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ithanet.eu%2F&amp;token=AxdOYZDP6%2F9e17f8kv7xVw%2FTmNc6CIizqT6OyPM%2B4bs%3D&amp;TOPIC_ID=90749" target="_blank">ithanet.eu</a>). A common polymorphism found in <em>HBG1,</em> where threonine replaces isoleucine at codon gamma 75, is known as Hb F Sardinia [<a href="#rid5">5</a>]. It has no clinical significance. Hb F variants that affect hemoglobin stability can result in anemia (due to hemolysis) or cyanosis (due to methemoglobin formation), but these effects are only seen in neonates, as they "disappear" when Hb F values decline and Hb F is replaced by Hb A. (See  <a class="medical medical_review" href="/d/html/7086.html" rel="external">"Unstable hemoglobin variants"</a> and  <a class="medical medical_review" href="/d/html/7164.html" rel="external">"Hemoglobin variants that alter hemoglobin-oxygen affinity"</a> and  <a class="medical medical_review" href="/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Hemoglobin M disease and cytochrome b5 deficiency'</a>.)</p><p></p><p class="headingAnchor" id="H2398241161"><span class="h2">Structural and functional properties of Hb F</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structural properties</strong> – Crystallographic studies of Hb F at 2.5 angstrom resolution show almost complete isomorphism between Hb A and Hb F, with the sole difference being located at the N-terminus [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1">Hb F has a strong globin-heme interaction and a lower rate of dimerization compared with Hb A [<a href="#rid7">7</a>]. Approximately 20 percent of Hb F in the developing fetus has an acetylated gamma globin N terminus [<a href="#rid8">8</a>]. An effect on Hb F function is likely minimal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amino acid sequence</strong> – Hb F and Hb A differ by 39 out of 146 amino acids. At position 87 the gamma (and delta) chain has a glutamine (Q) residue while the beta chain contains threonine (T). This single difference accounts in large part for the inhibitory effect of Hb F (and Hb A<sub>2</sub>) on Hb S polymerization [<a href="#rid9">9</a>]. Another residue contributing to the anti-polymerization effect of Hb F is aspartic acid at position 80. Glutamine (Q) 87 has been introduced into the Hb A gene (Hb A<sup>T87Q</sup>) as a gene addition therapy to successfully treat sickle cell disease and beta thalassemia. (See <a class="local">'Cell-based therapeutics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased oxygen affinity</strong> – A major functional difference between Hb F and Hb A is their oxygen (O<sub>2</sub>) affinity. The higher O<sub>2 </sub>affinity of Hb F allows preferential transfer of O<sub>2</sub> from the maternal to the fetal circulation during gestation. The P<sub>50</sub> (partial pressure at which the hemoglobin molecule is half saturated with O<sub>2</sub>)<sub> </sub>is approximately 19 torr in cells with primarily Hb F compared with approximately 27 torr for Hb A-containing cells  (<a class="graphic graphic_figure graphicRef81216" href="/d/graphic/81216.html" rel="external">figure 2</a>). High O<sub>2</sub> affinity is a feature of mammalian fetal hemoglobins, although a hemoglobin expressed predominantly in the fetal stage of development is not present in all mammals. </p><p></p><p class="bulletIndent1">The difference in O<sub>2</sub> affinity between Hb F and Hb A is primarily a result of the failure of Hb F to interact with the organic phosphate 2,3 BPG due to a serine at amino acid 143 in gamma globin, rather than the 143 histidine in beta globin. Solutions of Hb F in which organic phosphates have been removed have a P<sub>50</sub> identical to that of Hb A. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'Oxygen affinity'</a>.)</p><p></p><p class="bulletIndent1">This single amino acid difference also alters the Bohr effect, through which an increase in blood acidity (decrease in pH) causes a shift in the P<sub>50</sub> with increased release of O<sub>2</sub> from hemoglobin. The Bohr effect of Hb F is 20 percent higher than that of Hb A, which maximizes O<sub>2</sub> transport to the fetus, contributing to approximately half of the O<sub>2</sub> transport between mother and fetus. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins", section on 'pH'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkaline resistance</strong> – Hb F is more resistant to alkali compared with Hb A. Alkaline resistance may be due to two differences in the alpha1/gamma1 interface (gamma 112 threonine, which is a cysteine residue in beta globin, and gamma 130 tryptophan, which is a tyrosine in beta globin). This difference between Hb F and Hb A provided the basis for measuring Hb F by the historical but still used method of alkali denaturation [<a href="#rid10">10</a>]. The Kleihauer-Betke acid elution stain of blood smears is one method to detect maternal-fetal hemorrhage, although newer Hb F fluorescence activated cell sorting (FACS)-based methods are available [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/6806.html" rel="external">"Spontaneous massive fetomaternal hemorrhage", section on 'Kleihauer-Betke assay'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protection against malaria</strong> – A protective effect of Hb F against malaria is in part due to a stronger hemoglobin tetramer that less readily dissociates into digestible dimers [<a href="#rid12">12</a>]. Structural differences at amino acid positions 1, 5, and 7 in the amino-terminal alpha helix of gamma globin compared with beta globin account for the greater strength of the Hb F tetramer compared with Hb A [<a href="#rid13">13,14</a>]. Other mechanisms of malaria resistance conferred by Hb F might also occur [<a href="#rid15">15</a>]. However, some data have questioned the protective effects of Hb F on malaria [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/7099.html" rel="external">"Protection against malaria by variants in red blood cell (RBC) genes", section on 'Fetal hemoglobin'</a>.)</p><p></p><p class="headingAnchor" id="H3136974678"><span class="h3">Hemoglobin switching and downregulation of Hb F expression</span><span class="headingEndMark"> — </span>After the eighth week of gestation, Hb F replaces embryonic hemoglobins to become the predominant hemoglobin in the fetus, with values increasing until midway through gestation. The concentration of Hb F then decreases with increasing gestational age. If an infant is born prematurely at 28 weeks gestation, the concentration of Hb F is approximately 90 percent, decreasing to approximately 60 percent by 10 weeks after birth (38 weeks since conception) and equivalent to that of a full-term infant born at 38 weeks. (See  <a class="medical medical_review" href="/d/html/4962.html" rel="external">"Anemia of prematurity (AOP)", section on 'Physiologic consequences'</a>.)</p><p>After birth, Hb F is gradually but never totally replaced by Hb A, such that after approximately six months of age, Hb F comprises &lt;1 percent of total hemoglobin. Hb F values are largely genetically controlled, with some contribution by the dynamics of erythropoiesis, which might be influenced by environmental factors [<a href="#rid17">17</a>]. Complex genetic regulation explains the lack of clear Mendelian inheritance patterns in some patients with increased Hb F [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Causes of non-Mendelian inheritance'</a>.)</p><p>Switching from Hb F to Hb A involves repression of <em>HBG </em>(<em>HBG2</em> and<em> HBG1</em>)<em> </em>and upregulation of <em>HBB</em> expression. Some of the key regulators are illustrated in the figure  (<a class="graphic graphic_figure graphicRef131460" href="/d/graphic/131460.html" rel="external">figure 3</a>). </p><p>Hemoglobin switching is the result of developmentally timed inactivation and activation of genes within the <em>HBB</em> cluster [<a href="#rid20">20-26</a>]. Switching also occurs in the alpha globin gene cluster with many of the same transcription factors involved. However, it is expression of <em>HBG</em> that allows the formation of Hb F [<a href="#rid27">27</a>]. Transcription factors involved in nuclear chromatin remodeling (NuRD) complexes, along with epigenetic modulation via chromatin "writers," "readers," and "erasers," which effect histone methylation and acetylation (such as DNA methyltransferases and demethylases) and interact with the locus control region (LCR), a super-enhancer approximately 60 kb upstream of the <em>HBB</em> cluster. </p><p>The DNA of the LCR loops back around to the region of the globin gene promoters, recruiting transcription factors such as GATA1, TAL1, E2A, LMO2, and LDB1, leading to silencing of the embryonic and fetal genes and activation of the adult globin genes. During development, repressors of <em>HBG</em> are active, allowing expression of the adult genes. Other developmental factors modulating hemoglobin switching include:</p><p class="bulletIndent1"><span class="glyph">●</span>Long-noncoding (lnc) RNAs [<a href="#rid28">28,29</a>] </p><p class="bulletIndent1"><span class="glyph">●</span>LIN28</p><p class="bulletIndent1"><span class="glyph">●</span>IGF2BP</p><p class="bulletIndent1"><span class="glyph">●</span>RNA-binding factors</p><p class="bulletIndent1"><span class="glyph">●</span>Let-7 family microRNAs</p><p></p><p>Let-7 microRNAs are dramatically elevated in adult reticulocytes. Reduction of let-7, or over-expression of its regulator LIN28B, leads to increased <em>HBG </em>expression [<a href="#rid30">30</a>].</p><p>BCL11A (B cell lymphoma/leukemia 11A) and ZBTB7A (zinc finger and BTB domain-containing protein 7A; also called LRF [leukemia/lymphoma-related factor]) are the major repressors of <em>HBG</em> expression. When Hb F values are high, BCL11A values are very low or absent; as Hb F values fall, BCL11A values rise. LIN28B might also act independently of let-7 by directly binding BCL11A mRNA and preventing its effective translation. The absence of LIN28B expression in adult erythroid cells allows effective BCL11A protein synthesis, suppressing HBG expression [<a href="#rid31">31</a>].</p><p><em>ZBTB7A</em> encodes a zinc finger transcription factor with an effect on Hb F gene silencing similar to BCL11A. Its inactivation in the HUDEP-2 cell line that expresses predominantly Hb A led to an increase in Hb F to approximately 50 percent. And knockout of both <em>BCL11A</em> and <em>ZBTB7A</em> was associated with &gt;90 percent Hb F [<a href="#rid32">32</a>]. <em>ZBTB7A </em>is not polymorphic and does not appear to account for Hb F variation in individuals with sickle cell disease [<a href="#rid33">33</a>]. </p><p class="headingAnchor" id="H2314748054"><span class="h3">Quantitative trait loci associated with HBG expression</span><span class="headingEndMark"> — </span>Quantitative trait loci (QTL) are genes or genetic regions that affect quantitative phenotypes along a continuum. Traits such as height and weight and the common Hb F variation do not follow a mendelian pattern of inheritance. They are referred to as complex traits, and a combination of QTLs account for their variation. </p><p>Three QTL have large effects on Hb F values and are highly polymorphic (showing a high degree of variation). (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms", section on 'Quantitative traits and quantitative trait loci (QTL)'</a>.)</p><p>Polymorphisms within three QTL affect <em>HBG</em> expression:</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BCL11A</em></strong> – Polymorphisms<em> </em>rs654815 and rs1427407. (See <a class="local">'BCL11A'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>HBS1L</em></strong> and <strong><em>MYB</em></strong> intergenic region (<strong><em>HMIP</em></strong>)<em> – </em>Polymorphisms<em> </em>rs66650371 and rs9399137.<em> </em>(See <a class="local">'HBS1L-MYB intergenic region (HMIP)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>HBG2 </em></strong><strong>promotor</strong> (a locus in the promotor of <em>HBG2</em> marked by a recognition site for the restriction endonuclease Xmn1) – Polymorphism rs7482144. (See <a class="local">'HBG2 Xmn1 polymorphism'</a> below.)</p><p></p><p>In one study of 581 individuals homozygous for the Hb S gene or with Hb S-beta<sup>0 </sup>thalassemia, these four polymorphisms accounted for 22 percent of Hb F variability in cohorts of individuals with sickle cell anemia, Hb S-β<sup>0 </sup>thalassemia, and Hb SC disease [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H4278421792"><span class="h4"><i>BCL11A</i></span><span class="headingEndMark"> — </span><em>BCL11A</em> (chromosome 2p16) codes for a zinc finger transcription factor that was first identified as a major QTL for Hb F by genome-wide association studies (GWAS). </p><p>Despite the complexity of hemoglobin switching and the dozens of transcription factors and other elements involved, knockdown of <em>BCL11A</em> activity, either by disrupting its erythroid enhancer or altering its maj<em>or HBG </em>binding sites, increases Hb F sufficiently so that its clinical effects are profound. (See <a class="local">'Sickle cell disease'</a> below.) </p><p>The functional variants <em>of BCL11A </em>are marked by single nucleotide polymorphisms (SNPs; also called single nucleotide variants) localized to an erythroid-specific enhancer in the second intron of the gene [<a href="#rid35">35</a>]. The erythroid-specific enhancer <em>of BCL11A</em> consists of three DNase hypersensitive sites located +62, +58, and +55 kb from the transcription initiation site.<sup> </sup>The sentinel SNP marking this QTL is rs1427407 at the +62 locus. </p><p>The features of the enhancer elements that have the greatest effect on<em> HBG</em> expression have been defined at near nucleotide resolution [<a href="#rid36">36</a>]. Naturally occurring variants and CRISPR-Cas9 mediated disruption of the BCL11A -115 binding site increased<em> HBG</em> expression. A point mutation at position -113 that causes hereditary persistence of fetal hemoglobin (HPFH) does not disrupt BCL11A binding but rather creates a de novo binding site for the transcriptional activator GATA1, thereby increasing Hb F [<a href="#rid37">37</a>]. (See <a class="local">'Hereditary persistence of fetal hemoglobin (HPFH)'</a> below.)</p><p><em>BCL11A</em> enhancer variants associated with increased Hb F are present in approximately 20 percent of patients with sickle cell disease. The frequency of Hb F boosting variants differs among populations. BCL11A binds TGACCA motifs found at 35 sites in t<em>he HBB</em> gene cluster, preferentially binding around position -115 bp relative to the transcription initiation site and overlapping CCAAT boxes in t<em>he HBG</em> promoters. Turning<em> HBG</em> expression on or off is in large part a result of competition of BCL11A with NF-Y, the ubiquitous activator, for occupancy of the proximal CCAAT box of the<em> HBG</em> promoters; loss of either BCL11A or the transcription factor ZBTB7A increases chromatin accessibility, thereby allowing NF-Y to gain partial competitive advantage [<a href="#rid38">38</a>]. Reducing the expression of the <em>BCL11A</em> ortholog in transgenic sickle cell mice resulted in derepression of <em>HBG</em> [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H1723336571"><span class="h4">HBS1L-MYB intergenic region (HMIP)</span><span class="headingEndMark"> — </span><em>MYB</em> (chromosome 6q23) codes for a member of a large family of transcription factors that regulate cell cycle progression and differentiation; MYB regulates proliferation and maturation of erythroid cells and modulates gene expression within the <em>HBB</em> gene cluster.</p><p>The importance of <em>MYB</em> in regulating Hb F was first identified in a family from India and ultimately localized to variants in the intergenic region between <em>HBS1L</em> and <em>MYB</em> (also called <em>HMIP</em>, for HBS1L-MYB intergenic polymorphism, or <em>HBFQTL2</em>); this region contains an <em>MYB </em>enhancer<em> </em>[<a href="#rid40">40</a>]<em>.</em> Polymorphisms of this locus also impact platelet and monocyte counts, hematocrit, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) [<a href="#rid41">41,42</a>]. </p><p>The functional/causative variant in <em>HMIP</em> associated with high Hb F is a 3 bp deletion in an enhancer 84 kb upstream of<em> MYB</em> that is in complete linkage disequilibrium with the two sentinel polymorphisms noted above (rs9399137 and rs66650371). The region of the 3 bp deletion binds TAL1, E47 GATA, RUNX1, LDB1 and KLF1. A DNA fragment including the region of this deletion had enhancer-like activity that was augmented by the introduction of the 3 bp deletion. Downregulation of a lncRNA transcribed from this region increased <em>HBG</em> expression [<a href="#rid28">28,42-45</a>]. </p><p class="headingAnchor" id="H963009552"><span class="h4"><i>HBG2</i> Xmn1 polymorphism</span><span class="headingEndMark"> — </span>A polymorphism in the <em>HBG2 </em>promotor (chromosome 16) was the first Hb F QTL identified. (See <a class="local">'Gamma globin genes (HBG2 and HBG1)'</a> above.)</p><p>The <em>HBG2</em> Xmn1 polymorphism first came to attention when it was noted that patients with sickle cell disease who had the Senegal and Arab Indian haplotypes of sickle cell disease had relatively higher Hb F compared to patients with the other haplotypes. </p><p>The two haplotypes had in common a single nucleotide C-T polymorphism 158 bp upstream of<strong> </strong><em>HBG2</em>. CRISPR-Cas9 disruption of this site in CD34<sup>+</sup> cells from patients with sickle cell disease caused an increase in gamma globin to approximately 25 percent, and 55±5 percent F cells, compared with 30 to 40 percent gamma globin and 75 to 80 percent F cells when BCL11A and ZBTB7A binding sites, respectively, were disrupted.</p><p>While<sup> </sup><em>BCL11A </em>enhancer polymorphisms are associated with increased expression of both gamma globin genes only the <em>HBG2</em> allele is affected by the -158 polymorphism. The transcription factor(s) binding to the -158 <em>HBG2</em> motif are uncharacterized. </p><p class="headingAnchor" id="H478117958"><span class="h3">Other regulators of Hb F switching</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>KLF1</strong> – Kruppel-like factor 1 (KLF1) is a major erythroid transcription factor that activates <em>BCL11A</em> and <em>ZBTB7A</em> and promotes <em>HBB</em> expression, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef131460" href="/d/graphic/131460.html" rel="external">figure 3</a>) [<a href="#rid46">46-50</a>]. (See <a class="local">'Hemoglobin switching and downregulation of Hb F expression'</a> above and  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis", section on 'Krϋppel-like factor 1'</a>.)</p><p></p><p class="bulletIndent1">The role of the <em>KLF1</em> gene in Hb F expression was originally identified in a family with beta thalassemia and HPFH; affected individuals had a nonsense mutation (K288X) that disrupted the ability of KLF1 to bind DNA [<a href="#rid51">51</a>]. Subsequent reports describ<em>ed KLF1</em> variants in individuals with other RBC disorders [<a href="#rid52">52-60</a>]. </p><p></p><p class="bulletIndent1">The T to C polymorphism at position -198 of the <em>HBG1</em> gene promoter (responsible for British type HPFH) creates a binding site for KLF1 [<a href="#rid61">61</a>]. When this mutation was introduced into an erythroid cell line expressing Hb A, Hb F values rose substantially. </p><p></p><p class="bulletIndent1">KLF1 binds to the promoter of <em>ZBTB7A</em>, increasing its expression, and also increases expression of <em>BCL11A</em> repressing <em>HBG</em>. Reduced <em>KLF1</em> expression or activity is associated with Hb F derepression [<a href="#rid62">62,63</a>]. In CD34<sup>+</sup> human progenitor cells, base editing at -123 and -124 bp in the <em>HBG</em> promoters increased Hb F to putatively therapeutic values, perhaps by creating a de novo KLF1 binding site. </p><p></p><p class="bulletIndent1">KLF1 may also play a role in the silencing of <em>HBE </em>and<em> HBZ </em>expression [<a href="#rid57">57</a>]. Pathogenic variants in <em>KLF1</em> have also been reported to cause pyruvate kinase deficiency. (See  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1">A microRNA, miR-326, suppresses <em>KLF1</em> expression directly by targeting its 3' untranslated region [<a href="#rid50">50</a>]. </p><p></p><p class="bulletIndent1">The pseudogene <em>HHBBP1 </em>appears to have a roles in hemoglobin switching that may be related to effects on chromatin structure [<a href="#rid38">38,64-66</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors that regulate Hb F switching</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LSD1/CoREST (lysine-specific demethylase 1 and repressor element-1 silencing transcription factor corepressor), a histone demethylase complex [<a href="#rid67">67</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>SOX6, an<strong> </strong>HMG-box-containing transcription factor<strong> </strong>[<a href="#rid68">68</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>IGF2BP1 (insulin-like growth factor 2 mRNA-binding protein 1), a possible posttranscriptional regulator of BCL11A abundance [<a href="#rid69">69</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>LIN28B, a BCL11A mRNA binding protein that prevents translation [<a href="#rid31">31</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>PRMTs (protein arginine methyltransferases) that suppress translation [<a href="#rid70">70-72</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Other polymorphisms in the <em>HBB</em> cluster [<a href="#rid64">64,73-75</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>X-linked elements [<a href="#rid76">76,77</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>MicroRNAs-15a and 16-1, which contribute to <em>MYB</em> expression, and let-7 [<a href="#rid30">30,78</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Orphan nuclear receptors TR2/TR4 (part of the DRED complex) [<a href="#rid79">79-81</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Protein arginine methyltransferase PRMT5 [<a href="#rid82">82</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Ubiquitin ligase substrate speckle-type POZ protein (SPOP)</p><p class="bulletIndent2"><span class="glyph">•</span>Protein deacetylase SIRT1 [<a href="#rid83">83,84</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Zinc-finger protein POGZ [<a href="#rid85">85</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>FOXO3 [<a href="#rid86">86</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Translation initiation factor eIF2alpha [<a href="#rid87">87</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Sp1 transcription factor [<a href="#rid88">88</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>ZNF410, a DNA-binding protein that activates NuRD component CHD4 [<a href="#rid89">89-91</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>ANTXR1, an anthrax toxin receptor [<a href="#rid92">92,93</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Heme-regulated inhibitor (HRI) and downstream transcription factor ATF4 [<a href="#rid94">94,95</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Epigenetic regulators [<a href="#rid65">65,66,96,97</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><em>BGLT3</em> linc (long intergenic noncoding) RNA [<a href="#rid29">29</a>] </p><p></p><p>The emerging understanding of Hb F regulation has provided new insights and opportunities for therapeutic Hb F reactivation [<a href="#rid20">20,98,99</a>]. Therapeutic targeting of <em>BCL11A</em> expression or BCL11A binding and other strategies to turn off or reverse hemoglobin switching therapeutically are under clinical development to treat sickle cell disease and beta thalassemia. (See <a class="local">'Therapeutic approaches to Hb F modulation'</a> below and  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Increased Hb F production'</a> and  <a class="medical medical_review" href="/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Increasing Hb F'</a>.)</p><p class="headingAnchor" id="H1611772624"><span class="h2">F cells and F reticulocytes</span><span class="headingEndMark"> — </span>Erythrocytes containing enough Hb F to be detected by fluorescence activated cell sorting (FACS) are called F cells. F cell numbers correlate closely with Hb F values [<a href="#rid100">100</a>]. FACS can detect approximately 4 to 6 picograms (pg) of Hb F per cell [<a href="#rid101">101</a>]. More sensitive methods can detect approximately 2 pg of Hb F per cell and might be able to measure the distribution of Hb F concentrations among F cells [<a href="#rid102">102</a>]. The amount of Hb F per F cell remains stable as nucleated red cells become reticulocytes that mature to RBCs [<a href="#rid103">103</a>].</p><p>F reticulocytes estimate the expression of <em>HBG</em> better than F cells, because in sickle cell disease and beta thalassemia, F cells have a survival advantage in the circulation [<a href="#rid104">104</a>]. In biotin-labeled sickle cells, F cells survived six to eight weeks, compared with approximately two weeks for non-F cells [<a href="#rid105">105</a>].</p><p>After the first year of life, F cells account for &lt;4 percent of RBCs and F reticulocytes account for approximately 1 percent of circulating RBCs [<a href="#rid106">106</a>]. As with the percentage of Hb F, F cells in sickle cell trait (approximately 2 percent) are similar to those in individuals with Hb A, but increased in sickle cell disease (approximately 11 percent). </p><p class="headingAnchor" id="H1524975677"><span class="h1">CONDITIONS CAUSING INCREASED Hb F</span></p><p class="headingAnchor" id="H4183139587"><span class="h2">Overview of conditions with high Hb F</span><span class="headingEndMark"> — </span>The reference range for Hb F in adults is &lt;1 percent. (See  <a class="medical medical_society_guidelines" href="/d/html/115286.html" rel="external">"Laboratory test reference ranges in adults", section on 'Hemoglobin fractionation'</a>.)</p><p>Hb F values can be increased by heritable (genetic) and acquired conditions  (<a class="graphic graphic_table graphicRef94140" href="/d/graphic/94140.html" rel="external">table 1</a>); their effects on Hb F values are summarized in the table  (<a class="graphic graphic_table graphicRef141575" href="/d/graphic/141575.html" rel="external">table 2</a>) and illustrated in the schematic  (<a class="graphic graphic_figure graphicRef94394" href="/d/graphic/94394.html" rel="external">figure 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic causes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta thalassemia – (See <a class="local">'Beta thalassemia'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Delta-beta thalassemia – (See <a class="local">'Delta-beta thalassemia'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary persistence of fetal hemoglobin (HPFH) – (See <a class="local">'Hereditary persistence of fetal hemoglobin (HPFH)'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Sickle cell disease – (See <a class="local">'Sickle cell disease'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Minor alleles of Hb F quantitative trait loci (QTL) – (See <a class="local">'Quantitative trait loci associated with HBG expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired causes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> therapy – (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease", section on 'Increased Hb F production'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Erythropoietic stress such as pregnancy – (See  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis", section on 'Stress and erythropoiesis'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Miscellaneous other causes are summarized in the table  (<a class="graphic graphic_table graphicRef94140" href="/d/graphic/94140.html" rel="external">table 1</a>) and discussed below – (See <a class="local">'Secondary increases in Hb F'</a> below.)</p><p></p><p>When found serendipitously on high performance liquid chromatography (HPLC) analysis during diagnostic studies for anemias other than sickle cell disease or beta thalassemia and related conditions, increased Hb F usually has no clinical significance. </p><p>Population surveys show that the values of Hb F are usually &lt;1 percent, but nevertheless are highly variable within this range. F cells vary over 20-fold in adults without hemoglobinopathies; the distribution is continuous and positively skewed [<a href="#rid107">107-109</a>]. </p><p>For both Hb F and F cells, which are highly correlated, the variation is likely due to the influence of common Hb F boosting polymorphisms in the major Hb F QTLs along with many rare variants in these QTLs and elsewhere in the genome. (See <a class="local">'Quantitative trait loci associated with HBG expression'</a> above.)</p><p>The table  (<a class="graphic graphic_table graphicRef141575" href="/d/graphic/141575.html" rel="external">table 2</a>) lists typical Hb F values in different conditions. The highest values of Hb F are seen with severe, transfusion-dependent beta thalassemia or gene deletion HPFH, in which Hb F can range from 30 percent in heterozygous individuals to 100 percent in homozygous individuals. </p><p>Depending on patient age, <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> can increase Hb F to up to 40 percent. Delta-beta thalassemia and non-deletional HPFH can raise Hb F &gt;10 percent in individuals with sickle cell disease or Hb S-beta thalassemia. In adults with sickle cell disease in the absence of any treatment, Hb F can reach 25 percent, although in most patients of African descent it measures 5 to 8 percent. (See <a class="local">'Sickle cell disease'</a> below.)</p><p>Other findings on the complete blood count that can be helpful in distinguishing among these conditions include the presence of microcytosis, which suggests (but is not specific for) beta thalassemia. (See <a class="local">'Interpretation of high Hb F values'</a> below.)</p><p class="headingAnchor" id="H1767108385"><span class="h2">Beta thalassemia</span><span class="headingEndMark"> — </span>Hb F values are highest (from 10 to 100 percent) in transfusion dependent beta thalassemia and are normal or only slightly elevated (&gt;1 to 2 percent) in beta thalassemia trait [<a href="#rid110">110-112</a>]. In beta thalassemia trait, Hb F &gt;3 percent suggests co-inheritance of Hb F boosting variants of the major Hb F QTLs [<a href="#rid28">28,95</a>]. </p><p>Small deletions or point mutations of the promoter region of the <em>HBB</em> gene cause beta thalassemia with much higher values of Hb F than other thalassemia mutations. Perhaps these mutations favor locus control region (LCR) interactions with gamma globin gene promoters<em> </em>[<a href="#rid113">113,114</a>]. (See  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Overview of subtypes and disease severity'</a> and  <a class="medical medical_review" href="/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes"</a>.)</p><p class="headingAnchor" id="H720871149"><span class="h2">Hereditary persistence of fetal hemoglobin (HPFH)</span><span class="headingEndMark"> — </span>HPFH refers to a group of genetic variants within the <em>HBB</em> cluster that cause increased <em>HBG</em> expression and Hb F values. Individuals who are heterozygous and even homozygous for HPFH variants are asymptomatic. They are not anemic or are minimally anemic but often have microcytosis. </p><p>HPFH has gene deletion and non-gene deletion forms. Deletional HPFH is due to deletion of the genes encoding delta globin and beta globin, preserving one or both gamma globin genes. Non-deletional HPFH is due to point mutations or other small changes in the <em>HBG</em> promotors. In both forms, Hb F is usually pancellularly distributed (present in all red blood cells [RBCs]) when high Hb F values near 30 percent. Heterocellular distribution (Hb F present in a subset of RBCs) is typical with more modest elevations in Hb F.</p><p>High values of Hb F can be present without HPFH mutations. (See <a class="local">'Overview of conditions with high Hb F'</a> above.)</p><p class="headingAnchor" id="H2386519385"><span class="h3">Deletional HPFH</span></p><p class="bulletIndent1"><span class="glyph">●</span>Deletional HPFH (also called gene deletion HPFH) is caused by deletions in the <em>HBB</em> gene cluster from 13 to 106 kb that remove part or all of <em>HBD</em> and <em>HBB</em> and are associated with nearly complete compensatory increase in <em>HBG</em> expression and Hb F values  (<a class="graphic graphic_figure graphicRef94662" href="/d/graphic/94662.html" rel="external">figure 5</a>). These deletions are characteristically associated with a pancellular or homogenous distribution of Hb F among RBCs. It seems likely that each RBC does not have identical concentrations of Hb F; nevertheless, all cells have Hb F.</p><p></p><p class="bulletIndent1">HPFH 1 and HPFH 2 are the most common types of deletional HPFH in people of African descent. They are characterized by &gt;80 kb deletions that include <em>HBD</em> and <em>HBB</em> and are staggered by approximately 5 kb at the 5' and 3' ends. Heterozygous individuals have Hb F values of 20 to 30 percent and mild microcytosis. The ratio of G-gamma to A-gamma chains is approximately 50:50 in HPFH 1 and 30:70 in HPFH 2. Other HPFH deletions have similar hematologic findings with minor differences in the ratios of G-gamma to A-gamma chains. Homozygous individuals have 100 percent Hb F and no Hb A<sub>2</sub>. </p><p></p><p class="bulletIndent1">There is overlap between deletional HPFH and delta-beta thalassemia. Both are caused by deletions in the <em>HBB</em> gene cluster affecting <em>HBD</em> and <em>HBB</em>. In delta-beta thalassemia, the increase in gamma globin chain synthesis does not fully compensate for the loss of beta globin. (See <a class="local">'Delta-beta thalassemia'</a> below.)</p><p></p><p class="headingAnchor" id="H3313810114"><span class="h3">Non-deletion HPFH</span><span class="headingEndMark"> — </span>Non-deletion HPFH is caused by point mutations in either <em>HBG2</em> or <em>HBG1</em> promoters that alter transcription factor binding. Heterozygotes have Hb F values from 5 to 40 percent. These variants include single base substitutions and minor deletions clustered in two regions in the <em>HBG</em> promoters [<a href="#rid73">73,115</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Positions -114 to -117</p><p class="bulletIndent1"><span class="glyph">●</span>Positions -195 to -202 </p><p class="bulletIndent1"><span class="glyph">●</span>Position -175 (associated with the highest Hb F increases)</p><p></p><p>Transcription factors involved include [<a href="#rid116">116</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>BCL11A (position -115)</p><p class="bulletIndent1"><span class="glyph">●</span>ZBTB7A (position -200)</p><p class="bulletIndent1"><span class="glyph">●</span>TSp-1 elements (positions -195 to -202)</p><p class="bulletIndent1"><span class="glyph">●</span>GATA1, NFE-3, and NF-gamma (duplicated CCAAT boxes around position -117)</p><p></p><p>Some small deletions of critical regions o<em>f the HBG</em> promoters, for example a 13 nucleotide deletion of the<em> HBG1</em> promoter that included the CCAAT box, were associated with Hb F of approximately 30 percent that was distributed pancellularly [<a href="#rid117">117,118</a>]. </p><p class="headingAnchor" id="H3817284128"><span class="h3">Increased Hb F due to variants in QTLs modulating expression</span><span class="headingEndMark"> — </span>Minor heterocellular increases in Hb F in adults, often familial, and not always inherited in a Mendelian fashion or linked to the <em>HBB</em> cluster, were frequently combined together as if they were the same disorder and historically called heterocellular HPFH. Single nucleotide variants in the <em>BCL11A, HBS1L–MYB </em>intergenic region (<em>HMIP</em>)<em> </em>and<em> HBG2</em>-Xmn1 QTLs and gene rearrangements such as Atlanta HPFH and triplicated and quadruplicated gamma globin genes explain many of these instances [<a href="#rid119">119,120</a>]. (See <a class="local">'Cell-based therapeutics'</a> below.) </p><p class="headingAnchor" id="H3062119257"><span class="h2">Delta-beta thalassemia</span><span class="headingEndMark"> — </span>Deletions in the <em>HBB</em> gene cluster that remove the beta globin and delta globin genes (<em>HBB</em> and <em>HBD</em>) but spare one or both gamma globin genes  (<a class="graphic graphic_figure graphicRef94662" href="/d/graphic/94662.html" rel="external">figure 5</a>) can also cause a delta-beta thalassemia phenotype. </p><p>These deletions overlap in size with HPFH deletions but are generally smaller, with different 5' and 3' breakpoints. Hb F ranges from 5 to 15 percent in heterozygous individuals, and because of this it appears heterocellularly distributed. Lower Hb F does not completely compensate for the lack of beta globin, and a thalassemic phenotype results. Homozygous individuals have 100 percent Hb F, yet some individuals still have moderate anemia. (See  <a class="medical medical_review" href="/d/html/7131.html" rel="external">"Molecular genetics of the thalassemia syndromes", section on 'Delta-beta thalassemia'</a>.)</p><p>The mechanism of increased Hb F in delta-beta thalassemia is unclear; several hypotheses have been proposed [<a href="#rid73">73,121</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Removal of regulatory regions between <em>HBG1</em> and <em>HBD</em> that silence gamma globin expression, especially the Corfu deletion [<a href="#rid122">122-125</a>]. (See <a class="local">'Globin evolution and genomic organization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Removal of competition between promotors for transcription factors, allowing greater transcription of gamma globin genes. (See <a class="local">'Hemoglobin switching and downregulation of Hb F expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Translocation of 3’ distal enhancers into the proximity of gamma globin genes [<a href="#rid126">126,127</a>]. </p><p></p><p>Reports have described compound heterozygous individuals with the sickle cell variant on one <em>HBB</em> allele and delta-beta thalassemia on the other <em>HBB</em> allele [<a href="#rid128">128,129</a>]. While Hb F is between 30 and 50 percent and F cells can exceed 90 percent, the phenotype is variable, and complications of sickle cell disease have been described. This could be a result of the distributions of Hb F concentrations amongst F cells, where some cells might have less than fully protective Hb F values [<a href="#rid101">101</a>]. </p><p class="headingAnchor" id="H2177216514"><span class="h2">Sickle cell disease</span></p><p class="headingAnchor" id="H3459361051"><span class="h3">Impact of Hb F on sickle cell disease severity</span><span class="headingEndMark"> — </span>Hb F is the major modulator of the phenotypic severity of sickle cell disease  (<a class="graphic graphic_figure graphicRef94395" href="/d/graphic/94395.html" rel="external">figure 6</a>). Hb F prevents the polymerization of deoxy-sickle hemoglobin (Hb S) because its hybrid tetramer, alpha2betaS;gamma, cannot enter the polymer phase. Presence of Hb F also dilutes the intracellular Hb S concentration, a key factor in Hb S polymerization [<a href="#rid130">130-132</a>]. </p><p>The incidence of acute sickle vaso-occlusive events such as painful episodes and acute chest syndrome are inversely correlated with Hb F concentration; events linked to hemolysis such as priapism, chronic kidney disease, cerebrovascular disease, and pulmonary hypertension are affected by Hb F, but the effect is less pronounced than with vaso-occlusive events [<a href="#rid133">133-135</a>]. This is likely because even with increased Hb F values, the heterocellular distribution of Hb F and differences in its concentration from cell to cell allow some F cells with lower Hb F (and non-F cells) to lyse within the circulation and release sufficient free heme to reduce nitric oxide bioavailability, a key determinant of the pathophysiology associated with intravascular hemolysis. (See  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Vaso-occlusion'</a> and  <a class="medical medical_review" href="/d/html/7135.html" rel="external">"Pathophysiology of sickle cell disease", section on 'Hemolysis'</a>.)</p><p>In large population-based studies, any increment in Hb F had a beneficial effect on morbidity and mortality [<a href="#rid136">136-138</a>]. When Hb F values are approximately 40 percent after gene therapy, nearly every cell has sufficient Hb F to prevent Hb S polymer-induced injury, and the phenotype of sickle cell disease is reversed [<a href="#rid139">139,140</a>]. (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p>Modeling studies suggest that 9 to 12 pg of Hb F per F cell can nearly totally protect the cell from Hb S polymer-induced damage [<a href="#rid141">141</a>]. The higher the Hb F value, the more likely there are to be more cells with protective Hb F concentrations. (See  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a>.)</p><p class="headingAnchor" id="H3895059240"><span class="h3">Genetic regulation of Hb F in sickle cell disease</span><span class="headingEndMark"> — </span>Three main contributing factors are the background haplotype, QTL polymorphisms, and HPFH.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Haplotypes</strong> – The sickle cell point mutation is associated with five common haplotypes (variants that cosegregate with the sickle cell mutation, generally associated with a geographic region or racial/ethnic group). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arab-Indian</p><p class="bulletIndent2"><span class="glyph">•</span>Senegal </p><p class="bulletIndent2"><span class="glyph">•</span>Benin</p><p class="bulletIndent2"><span class="glyph">•</span>Bantu</p><p class="bulletIndent2"><span class="glyph">•</span>Cameroon</p><p></p><p>These haplotypes are associated with different Hb F values in homozygous individuals. Untreated adults who are homozygous for the Arab-Indian haplotype have a mean Hb F of 17 percent; Senegal haplotype patients have Hb F of approximately 10 percent [<a href="#rid142">142,143</a>]. </p><p>In patients with the Benin, Bantu and Cameroon haplotype, the Hb F value of individuals of African and Arab descent appear to differ. Benin haplotype patients of African descent have Hb F of 6 percent; Saudi-Arab patients with the Benin haplotype have Hb F of 11 percent [<a href="#rid144">144</a>]. A similar increment in Hb F is found in patients of Saudi origin with the Bantu and Cameroon haplotypes [<a href="#rid145">145</a>]. </p><p>As children, untreated patients with the Arab-Indian haplotype have Hb F of approximately 30 percent [<a href="#rid145">145-147</a>]. As Hb F values decline, the phenotype of adults with the haplotype begins to resemble that of African patients. </p><p>Ascertainment of Hb S gene haplotype in individual patients has little prognostic value. Besides the -158 Xmn1 C-T polymorphism seen in Senegal and Arab-Indian haplotypes, the genetic and mechanistic basis of the variance of Hb F values in other Hb S gene haplotypes is undefined. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>QTL polymorphisms</strong> – Some of the baseline Hb F increase in sickle cell disease is related to polymorphisms in the three QTL modulating <em>HBG</em> expression [<a href="#rid64">64,75,144,146,148-170</a>]. (See <a class="local">'Quantitative trait loci associated with HBG expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HPFH</strong> – Individuals who are compound heterozygous for Hb S and deletion HPFH can have Hb F values of approximately 30 percent, with approximately 10 pg of Hb F in all RBCs. (See <a class="local">'Hereditary persistence of fetal hemoglobin (HPFH)'</a> above and  <a class="medical medical_review" href="/d/html/7115.html" rel="external">"Overview of compound sickle cell syndromes", section on 'Sickle-hereditary persistence of fetal hemoglobin'</a>.)</p><p></p><p class="bulletIndent1">This value of Hb F protects all cells from Hb S polymer-induced damage. In a series of 30 individuals with Hb S-HPFH in which the HPFH variant was molecularly defined, Hb F values were 50 to 90 percent during infancy and stabilized between ages 3 and 5 years at approximately 30 percent [<a href="#rid171">171</a>]. Patients were healthy without complications. </p><p></p><p class="bulletIndent1">Acute vaso-occlusive events have occasionally been reported in Hb S-HPFH, but the molecular basis of the high Hb F was not always characterized [<a href="#rid128">128</a>]. </p><p></p><p class="headingAnchor" id="H230492"><span class="h2">Secondary increases in Hb F</span><span class="headingEndMark"> — </span>Increased Hb F values in the postneonatal period have been found in various acquired and genetic disorders  (<a class="graphic graphic_table graphicRef94140" href="/d/graphic/94140.html" rel="external">table 1</a>). In most cases, the increases appear to be secondary to perturbation of erythropoiesis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prematurity</strong> – The switch from fetal to adult hemoglobin production proceeds on a set developmental clock and is not affected by the gestational age of the infant [<a href="#rid172">172</a>]. Hb F remains the major hemoglobin synthesized up to 37 weeks gestation. In early preterm newborns, timing of the transition from Hb F to Hb A synthesis postnatally resembles that in utero. (See <a class="local">'Hemoglobin switching and downregulation of Hb F expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants of diabetic mothers</strong> – Full-term infants of diabetic mothers have a delayed Hb F to Hb A switch and higher Hb F than expected for gestational age; this occurs via an unclear mechanism [<a href="#rid173">173,174</a>]. Elevated alpha-amino-butyric acid was proposed as a mechanism, but trials of butyrate analogues to raise Hb F in sickle cell disease were inconclusive [<a href="#rid175">175-178</a>]. (See  <a class="medical medical_review" href="/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Increasing Hb F'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trisomy 13</strong> – Individuals with trisomy 13 have a delayed Hb F to Hb A switch and persistently elevated Hb F values [<a href="#rid179">179,180</a>].<sup> </sup>One study suggested this was due to increased expression of microRNAs 15a and 16-1 produced from the triplicated chromosome 13 [<a href="#rid181">181</a>]. These microRNAs downregulate <em>MYB</em>. (See  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 13 syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased erythropoiesis</strong> – A number of conditions associated with stress erythropoiesis have been associated with increases in Hb F [<a href="#rid182">182</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow recovery </strong>–<strong> </strong>Bone marrow regeneration and acute expansion in erythropoietic activity have been proposed to underlie increases in F cells and Hb F in many leukemia patients following chemotherapy [<a href="#rid183">183</a>], after hematopoietic stem cell transplantation [<a href="#rid184">184</a>],<sup> </sup>following acute blood loss, and after treatment with iron in severe untreated iron deficiency [<a href="#rid185">185</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transient erythroblastopenia of childhood</strong> – Transient erythroblastopenia of childhood (TEC) is characterized by a transient arrest in erythropoiesis during which Hb F is not elevated. Spontaneous recovery is characterized by a brisk reticulocytosis and is typically associated with increased numbers of F cells and Hb F concentration [<a href="#rid185">185,186</a>]. (See  <a class="medical medical_review" href="/d/html/5931.html" rel="external">"Overview of causes of anemia in children due to decreased red blood cell production", section on 'Transient erythroblastopenia of childhood'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemolysis </strong>–<strong> </strong>Acute hemolysis also results in increased F cell production, likely due to the acute compensatory expansion in erythropoietic activity. In some studies, F cell numbers were increased [<a href="#rid184">184,185</a>]. Hb F values also rose with an increase in reticulocyte count. Co-inheritance of some HPFH variants or Hb F-boosting alleles in QTLs might explain this variability [<a href="#rid186">186</a>]. (See <a class="local">'Hereditary persistence of fetal hemoglobin (HPFH)'</a> above and <a class="local">'Quantitative trait loci associated with HBG expression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy</strong> – Increases in Hb F during pregnancy reach a peak in the second trimester. In one study, Hb F value during pregnancy was 0.71±0.51 percent, while in the nonpregnant control group it was 0.28±0.35 percent [<a href="#rid187">187</a>]. Increased production of F cells is the physiologic result of erythroid expansion during this period [<a href="#rid188">188</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Inherited bone marrow failure syndromes</strong> – Patients with inherited bone marrow failure syndromes (Diamond-Blackfan anemia, dyskeratosis congenita, Fanconi anemia, Shwachman-Diamond syndrome) frequently have increased Hb F as a component of stress hematopoiesis [<a href="#rid189">189</a>]. A wide range of Hb F increases has been observed. One study found an association of increased Hb F with young age, male sex, anemia, high erythropoietin values, and the minor allele (T) of the Xmn1-<em>HBG2</em> QTL [<a href="#rid190">190</a>]. (See  <a class="medical medical_review" href="/d/html/131283.html" rel="external">"Diamond-Blackfan anemia", section on 'Laboratory findings'</a> and <a class="local">'HBG2 Xmn1 polymorphism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancies</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>JMML</strong> – Increased Hb F values have been observed in juvenile myelomonocytic leukemia (JMML; also called juvenile chronic myeloid leukemia) and other hematologic malignancies [<a href="#rid191">191,192</a>]. In a retrospective review of 100 children &lt;16 years with JMML, Hb F comprised up to 90 percent of total hemoglobin in those with normal karyotype and chromosomal abnormalities other than monosomy 7 [<a href="#rid193">193</a>]. It was initially proposed that this was due to emergence of a clone of hematopoietic cells that had reverted to fetal erythropoiesis, but the uncoordinated expression of the various "fetal" characteristics suggested grossly distorted regulation of gene expression [<a href="#rid194">194</a>]. Hb F values appeared to be an independent risk factor of survival in the patients who did not undergo hematopoietic stem cell transplant [<a href="#rid193">193</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other hematologic malignancies </strong>– Some karyotypic abnormalities associated with myelodysplastic syndrome (MDS) have been associated with increased Hb F; Hb F &gt;10 percent was correlated with worse prognosis in one study [<a href="#rid195">195,196</a>]. Increased Hb F has also been reported in acute myeloid leukemia (AML), erythroleukemia, lymphoblastic leukemia, and chronic myeloid leukemia [<a href="#rid191">191</a>]. </p><p></p><p class="bulletIndent2">A 2017 study suggested that Hb F could be a predictor of outcome in MDS and AML but genetic variants associated with Hb F were not evaluated [<a href="#rid197">197</a>]. </p><p></p><p class="bulletIndent2">A 2022 study showed that the common genetic Hb F QTL variants influence Hb F and other hematological traits in patients with myeloproliferative neoplasms, multiple myeloma, and myelodysplasia, both at baseline and in response to Hb F-inducing cytotoxic therapy [<a href="#rid198">198</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Solid tumors</strong> – Rarely, increased Hb F values have been observed in solid tumors including choriocarcinoma, adenocarcinoma of the lung, and hepatoma [<a href="#rid199">199-201</a>]. The increased Hb F could be related to paraneoplastic phenomenon that involves inappropriate overproduction of erythropoietin [<a href="#rid202">202</a>].</p><p></p><p>Increased Hb F values have also been recorded in sporadic reports of thyrotoxicosis and pernicious anemia [<a href="#rid203">203</a>]. Review of a larger number of patients showed that increased Hb F is not a consistent feature. </p><p class="headingAnchor" id="H359562966"><span class="h1">EVALUATING Hb F VALUES AND INCREASED Hb F</span></p><p class="headingAnchor" id="H1187170135"><span class="h2">When to assay Hb F</span><span class="headingEndMark"> — </span>Measuring the Hb F value is most commonly used in monitoring <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy in individuals sickle cell disease and in diagnosis of hemoglobinopathies, where the value of Hb F and other hemoglobins helps confirm or eliminate specific diagnoses. </p><p>The values of Hb F and Hb A<sub>2</sub> (along with red blood cell [RBC] indices) help to distinguish beta thalassemia, delta-beta thalassemia, and hereditary persistence of fetal hemoglobin (HPFH). (See <a class="local">'Overview of conditions with high Hb F'</a> above and <a class="local">'Interpretation of high Hb F values'</a> below.)</p><p>Most clinicians will see the results for the Hb F value when hemoglobin fractionation is performed by high performance liquid chromatography (HPLC) or capillary electrophoresis, as Hb F is reported, similar to Hb A<sub>2</sub>. These analyses are usually ordered for the diagnosis of hemoglobinopathies and thalassemia. Slight Hb F increases in the absence of hemoglobin disorders rarely has clinical significance. </p><p>It is important not to overinterpret increased Hb F in an individual who does not have a hemoglobinopathy. Older forms of hemoglobin electrophoresis do not provide accurate measurement of Hb F.</p><p class="headingAnchor" id="H246931133"><span class="h2">Which test to order</span><span class="headingEndMark"> — </span>Hb F can be assessed in several ways: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein chemistry methods </strong>– These are often used for beta hemoglobinopathies. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High performance liquid chromatography (HPLC)  (<a class="graphic graphic_figure graphicRef72323" href="/d/graphic/72323.html" rel="external">figure 7</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Capillary electrophoresis  (<a class="graphic graphic_figure graphicRef65032" href="/d/graphic/65032.html" rel="external">figure 8</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Alkaline denaturation [<a href="#rid10">10</a>]</p><p></p><p class="bulletIndent1">HPLC and capillary electrophoresis are the most commonly used methods. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Protein chemistry methods'</a>.)</p><p></p><p class="bulletIndent1">When Hb S is also present, capillary electrophoresis gives a small but statistically significant higher Hb F value than HPLC [<a href="#rid204">204</a>]. </p><p></p><p class="bulletIndent1">Alkaline and acid hemoglobin electrophoresis  (<a class="graphic graphic_figure graphicRef68806" href="/d/graphic/68806.html" rel="external">figure 9</a>) and isoelectric focusing  (<a class="graphic graphic_figure graphicRef52896" href="/d/graphic/52896.html" rel="external">figure 10</a>) are useful for separation of major hemoglobin fractions but do not provide quantitative information on Hb F values. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DNA-based methods</strong> – DNA testing cannot determine the percentage of Hb F, but it can be used to identify variants in beta globin genes that cause hemoglobinopathies and in genes that control <em>HBG</em> expression. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Molecular genetic (DNA-based) methods'</a>.)</p><p></p><p>Counting F cells by flow cytometry is available in some research laboratories but is not commercially available. (See <a class="local">'Resources for testing'</a> below.)</p><p class="headingAnchor" id="H3313883366"><span class="h2">Interpretation of high Hb F values</span><span class="headingEndMark"> — </span>The reference range for Hb F is stated to be &lt;1 percent. A study using HPLC in adults without a hemoglobinopathy found Hb F concentrations were between 0.1 and 0.4 percent [<a href="#rid205">205</a>]. (See  <a class="medical medical_society_guidelines" href="/d/html/115286.html" rel="external">"Laboratory test reference ranges in adults", section on 'Hemoglobin fractionation'</a>.)</p><p>The table lists typical Hb F values in different conditions  (<a class="graphic graphic_table graphicRef141575" href="/d/graphic/141575.html" rel="external">table 2</a>). </p><p>Increased Hb F should be evaluated using the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Percentage of Hb F, Hb A</strong><strong><sub>2</sub></strong><strong>, and RBC indices</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hb F of 20 to 100 percent is typically due to transfusion-dependent beta thalassemia or some type of HPFH. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hb F of 10 to 20 percent, when accompanied by hypochromic microcytic RBCs and normal Hb A<sub>2</sub>, may indicate delta-beta thalassemia or nontransfusion-dependent beta thalassemia. In individuals without a hemoglobinopathy, Hb F of 2 to 10 percent with minimally affected RBC indices suggests co-inheritance of Hb F boosting polymorphism(s) in the quantitative trait loci (QTL) modulating <em>HBG</em> expression. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Slightly increased Hb F (2 to 3 percent) with hypochromic microcytic RBCs and elevated Hb A<sub>2</sub> suggests heterozygous beta thalassemia. (See <a class="local">'Quantitative trait loci associated with HBG expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient age</strong> – Hb F represents approximately 60 to 80 percent of total hemoglobin in the full-term newborn. By approximately 6 to 12 months of age, Hb F is almost completely replaced by Hb A. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood smear</strong> – Findings on the blood smear, especially sickled cells (indicative of sickle cell disease) or target cells (indicative of thalassemia) are critical for interpretation. (See  <a class="medical medical_review" href="/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders", section on 'Findings in sickle cell anemia'</a> and  <a class="medical medical_review" href="/d/html/7113.html" rel="external">"Diagnosis of sickle cell disorders", section on 'Diagnostic patterns in other sickle cell disorders'</a> and  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'CBC and hemolysis testing'</a>.)</p><p></p><p>Additional information on interpretation is presented separately. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Clues from the CBC'</a> and  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Common clinical scenarios'</a>.)</p><p class="headingAnchor" id="H1356229"><span class="h2">Resources for testing</span><span class="headingEndMark"> — </span>Making a specific diagnosis can be accomplished in most clinical laboratories. However, some conditions such as HPFH and delta-beta thalassemia may require DNA-based (molecular) methods. (See  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Referral to a specialized laboratory'</a>.)</p><p>The decision concerning which reference laboratory to send the sample to depends upon several factors. Many hospitals and medical centers have contractual agreements with one of the national reference laboratories and send the samples to these laboratories for further analysis. Some institutions prefer to send samples to one of the few laboratories that specialize in globin abnormalities  (<a class="graphic graphic_table graphicRef139930" href="/d/graphic/139930.html" rel="external">table 3</a>). This choice may depend upon the familiarity of the referring clinician. </p><p>A few academic laboratories in the United States specialize in evaluating globin abnormalities. </p><p class="bulletIndent1"><span class="glyph">●</span>Titus HJ Huisman Hemoglobinopathy Laboratory at Augusta University, Augusta, GA (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.augusta.edu%2Fcenters%2Fblood-disorders%2Fhemoglobinopathy%2Findex.php&amp;token=i7kljUOMUxw1WVWx1eA%2FH8%2BOtana%2F07I9uJHeWVCN8IJgBErryivR2WAv8sQI%2BWZj8m1Ojzr6cK1ruMuknJY3boEL%2FdVc6PTm7c0Im49qgg%3D&amp;TOPIC_ID=90749" target="_blank">https://www.augusta.edu/centers/blood-disorders/hemoglobinopathy/index.php</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin Diagnostic Reference Laboratory at Boston University, Boston, MA (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bu.edu%2Fsicklecell%2Fdiagnostics%2F&amp;token=wkK3meDdGl8H0MjoHsM%2FR3emawx2283oj756a42D57ZeLQCPborMvhl43wZlEy8eVw1AWN%2BosSj3j8P%2Bqkzumg%3D%3D&amp;TOPIC_ID=90749" target="_blank">https://www.bu.edu/sicklecell/diagnostics/</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobinopathy Laboratory at UCSF Benioff Children's Hospital, Oakland, CA (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.childrenshospitaloakland.org%2Fmain%2Fdepartments-services%2Fhemoglobinopathy-laboratory-123.aspx&amp;token=uJbiIxzqxaiSE%2BR43tHhDEQSRpbhWgFP49ikM7BY%2FvjYV9TudaWv%2FUykJiHgXmr7HN8P2fHkPcIh2TUXUAx7lEH7JoHMxFlmhJt2a6YnfA1CVZhgPjEgsItAAHU4LBFF&amp;TOPIC_ID=90749" target="_blank">https://www.childrenshospitaloakland.org/main/departments-services/hemoglobinopathy-laboratory-123.aspx</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte Diagnostic Lab, Cancer and Blood Diseases Institute, Cincinnati Children's, Cincinnati, OH (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cincinnatichildrens.org%2Fservice%2Fc%2Fcancer-blood%2Fhcp%2Fclinical-laboratories%2Ferythrocyte-diagnostic-lab&amp;token=bAo6sY1hY3mZukqj2l4FwYv5%2FnnHo7EmecoqokHcTM5M14FY%2B33kVzlWYLtbqCq%2Btxaz89PV4alDxVSjekXqo8uW9xnnuJw7kHxHI%2FpxP2HSM09wAGu8gMa6YCg6wLBc&amp;TOPIC_ID=90749" target="_blank">https://www.cincinnatichildrens.org/service/c/cancer-blood/hcp/clinical-laboratories/erythrocyte-diagnostic-lab</a>)</p><p></p><p class="headingAnchor" id="H3635428369"><span class="h1">THERAPEUTIC APPROACHES TO Hb F MODULATION</span></p><p class="headingAnchor" id="H4026878869"><span class="h2">Drug therapies</span><span class="headingEndMark"> — </span>Drugs that increase Hb F production are of interest because they have the potential to ameliorate disease manifestations of the beta hemoglobinopathies. <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is the only US Food and Drug Administration (FDA)-approved agent that can increase Hb F values, although others are in clinical trials [<a href="#rid87">87,142,206-210</a>]. (See  <a class="medical medical_review" href="/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Increasing Hb F'</a> and  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Investigational approaches'</a>.)</p><p class="headingAnchor" id="H1288786304"><span class="h2">Cell-based therapeutics</span><span class="headingEndMark"> — </span>Genetic manipulations that increase Hb F production or produce a "Hb F-like" Hb A (gene therapies) have the potential to provide curative therapy, although many aspects of these therapies require further study.</p><p class="bulletIndent1"><span class="glyph">●</span>Lentiviral-mediated gene addition of a fetal-like Hb A (Hb A<sup>T87Q</sup>)</p><p class="bulletIndent1"><span class="glyph">●</span>Lentiviral-mediated short hairpin RNA (shRNA) knockdown of BCL11A</p><p class="bulletIndent1"><span class="glyph">●</span>Targeting Hb F repressors using gene editing, base editing, and prime editing</p><p></p><p>Trials in sickle cell disease and beta thalassemia using mobilized autologous CD34<sup>+</sup> cells where the therapeutic construct is introduced in vitro and the altered cells reinfused following myeloablative conditioning have produced dramatic initial clinical successes, leading to almost 100 percent F cells and eliminating disease complications [<a href="#rid139">139,211</a>]. </p><p>These gene therapies either disrupt the <em>BCL11A</em> erythroid-specific enhancer using CRISPR-Cas9, interfere with enhancer function by its targeting with an shRNA, or add the Hb F-like Hb A, gene Hb A<sup>T87Q</sup>. The FDA has approved gene therapy with Hb A<sup>T87Q</sup> for severe beta thalassemia, and gene therapies for sickle cell disease are under investigation [<a href="#rid212">212</a>]. (See  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia"</a> and  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Gene editing'</a>.) </p><p class="headingAnchor" id="H359562972"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb F structure</strong> – Fetal hemoglobin (Hb F) is a tetramer of alpha and gamma globin (alpha2gamma2) that predominates during fetal development. Gamma globin is produced from two gamma globin genes (arranged in the beta globin locus with <em>HBG2</em> upstream of <em>HBG1</em>)  (<a class="graphic graphic_figure graphicRef65642" href="/d/graphic/65642.html" rel="external">figure 1</a>). Compared with adult hemoglobin (Hb A; alpha2beta2), Hb F has slightly increased oxygen (O<sub>2</sub>) affinity, which facilitates O<sub>2</sub> delivery to the fetus during gestation. (See <a class="local">'Globin evolution and genomic organization'</a> above and <a class="local">'Gamma globin genes (HBG2 and HBG1)'</a> above and <a class="local">'Structural and functional properties of Hb F'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regulation </strong>– The switch from Hb F to Hb A occurs shortly after birth; the figure illustrates major regulatory factors  (<a class="graphic graphic_figure graphicRef131460" href="/d/graphic/131460.html" rel="external">figure 3</a>). The degree of Hb F expression is a quantitative trait with multiple influences; the main quantitative trait loci (QTL) are the genes <em>BCL11A</em> and the <em>HBS1L</em>-<em>MYB </em>intergenic region (<em>HMIP</em>), which encode transcription factors, and the Xmn1 polymorphism in the <em>HBG2</em> promoter. (See <a class="local">'Hemoglobin switching and downregulation of Hb F expression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of high Hb F</strong> – The table summarizes conditions with increased Hb F and typical Hb F values in these conditions  (<a class="graphic graphic_table graphicRef141575" href="/d/graphic/141575.html" rel="external">table 2</a>). Common examples of genetic causes include beta thalassemia, hereditary persistence of fetal hemoglobin (HPFH; deletional and non-deletional), delta-beta thalassemia, and sickle cell disease. Secondary causes include stress erythropoiesis and others  (<a class="graphic graphic_table graphicRef94140" href="/d/graphic/94140.html" rel="external">table 1</a>). HPFH is a benign condition that generally does not cause anemia or other findings. (See <a class="local">'Conditions causing increased Hb F'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluating Hb F</strong> – Hb F value is most commonly measured using protein chemistry methods to monitor <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> therapy or transfusions in individuals with sickle cell disease and in diagnosis of hemoglobinopathies, where the value of Hb F and other hemoglobins helps confirm or eliminate specific diagnoses. The reference range in the absence of hemoglobinopathy is &lt;1 percent. Resources for testing are listed in the table  (<a class="graphic graphic_table graphicRef139930" href="/d/graphic/139930.html" rel="external">table 3</a>) and discussed above. When found serendipitously, increased Hb F rarely has clinical significance; it is important not to overinterpret this finding. (See <a class="local">'Evaluating Hb F values and increased Hb F'</a> above and  <a class="medical medical_review" href="/d/html/13941.html" rel="external">"Methods for hemoglobin analysis and hemoglobinopathy testing", section on 'Initial evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hb F manipulation</strong> – Therapeutic targeting of Hb F using medications such as <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> or genetic manipulations of gamma globin regulators, especially <em>BCL11A</em>, is being used or tested in sickle cell disease and beta thalassemia. (See <a class="local">'Therapeutic approaches to Hb F modulation'</a> above and  <a class="medical medical_review" href="/d/html/7071.html" rel="external">"Hydroxyurea use in sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hemoglobins</strong> – Other normal hemoglobins and other aspects of red blood cell (RBC) production are discussed separately. (See  <a class="medical medical_review" href="/d/html/7072.html" rel="external">"Structure and function of normal hemoglobins"</a> and  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p></p><p class="headingAnchor" id="H1886531844"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hardison RC. Evolution of hemoglobin and its genes. Cold Spring Harb Perspect Med 2012; 2:a011627.</a></li><li><a class="nounderline abstract_t">Slightom JL, Blechl AE, Smithies O. Human fetal G gamma- and A gamma-globin genes: complete nucleotide sequences suggest that DNA can be exchanged between these duplicated genes. Cell 1980; 21:627.</a></li><li><a class="nounderline abstract_t">Adachi K, Kim J, Asakura T, Schwartz E. Characterization of two types of fetal hemoglobin: alpha 2G gamma 2 and alpha 2A gamma 2. Blood 1990; 75:2070.</a></li><li><a class="nounderline abstract_t">Bard H, Peri KG, Gagnon C. Changes in the G gamma- and A gamma-globin mRNA components of fetal hemoglobin during human development. Biol Neonate 2001; 80:26.</a></li><li><a class="nounderline abstract_t">Ricco G, Mazza U, Turi RM, et al. Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine replaced by threonine at position 75 )E 19) of the gamma chain. Hum Genet 1976; 32:305.</a></li><li><a class="nounderline abstract_t">Frier JA, Perutz MF. Structure of human foetal deoxyhaemoglobin. J Mol Biol 1977; 112:97.</a></li><li><a class="nounderline abstract_t">McDonald MJ, Turci SM, Mrabet NT, et al. The kinetics of assembly of normal and variant human oxyhemoglobins. J Biol Chem 1987; 262:5951.</a></li><li><a class="nounderline abstract_t">SCHROEDER WA, CUA JT, MATSUDA G, FENNINGER WD. Hemoglobin F1, an acetyl-containing hemoglobin. Biochim Biophys Acta 1962; 63:532.</a></li><li><a class="nounderline abstract_t">Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979; 76:670.</a></li><li><a class="nounderline abstract_t">BETKE K, MARTI HR, SCHLICHT I. Estimation of small percentages of foetal haemoglobin. Nature 1959; 184(Suppl 24):1877.</a></li><li><a class="nounderline abstract_t">Kim YA, Makar RS. Detection of fetomaternal hemorrhage. Am J Hematol 2012; 87:417.</a></li><li><a class="nounderline abstract_t">Shear HL, Grinberg L, Gilman J, et al. Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism. Blood 1998; 92:2520.</a></li><li><a class="nounderline abstract_t">Yagami T, Ballard BT, Padovan JC, et al. N-terminal contributions of the gamma-subunit of fetal hemoglobin to its tetramer strength: remote effects at subunit contacts. Protein Sci 2002; 11:27.</a></li><li class="breakAll">Handin RI. Disorders of hemoglobin function and stability. In: Blood: Principles and practice of hematology, Handin RI, Lux SE, Stossel TP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1995. p.159.</li><li><a class="nounderline abstract_t">Amaratunga C, Lopera-Mesa TM, Brittain NJ, et al. A role for fetal hemoglobin and maternal immune IgG in infant resistance to Plasmodium falciparum malaria. PLoS One 2011; 6:e14798.</a></li><li><a class="nounderline abstract_t">Archer NM, Petersen N, Duraisingh MT. Fetal hemoglobin does not inhibit Plasmodium falciparum growth. Blood Adv 2019; 3:2149.</a></li><li><a class="nounderline abstract_t">Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 2000; 95:342.</a></li><li><a class="nounderline abstract_t">Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009; 145:455.</a></li><li><a class="nounderline abstract_t">Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet 2009; 18:R216.</a></li><li><a class="nounderline abstract_t">Vinjamur DS, Bauer DE, Orkin SH. Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br J Haematol 2018; 180:630.</a></li><li><a class="nounderline abstract_t">Ikawa Y, Miccio A, Magrin E, et al. Gene therapy of hemoglobinopathies: progress and future challenges. Hum Mol Genet 2019; 28:R24.</a></li><li><a class="nounderline abstract_t">Blobel GA, Bodine D, Brand M, et al. An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference. Exp Hematol 2015; 43:821.</a></li><li><a class="nounderline abstract_t">Menzel S, Thein SL. Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease. Mol Diagn Ther 2019; 23:235.</a></li><li><a class="nounderline abstract_t">Orkin SH, Bauer DE. Emerging Genetic Therapy for Sickle Cell Disease. Annu Rev Med 2019; 70:257.</a></li><li><a class="nounderline abstract_t">Lettre G, Bauer DE. Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. Lancet 2016; 387:2554.</a></li><li><a class="nounderline abstract_t">Wienert B, Martyn GE, Funnell APW, et al. Wake-up Sleepy Gene: Reactivating Fetal Globin for β-Hemoglobinopathies. Trends Genet 2018; 34:927.</a></li><li><a class="nounderline abstract_t">King AJ, Higgs DR. Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of α-thalassemia. Hematology Am Soc Hematol Educ Program 2018; 2018:353.</a></li><li><a class="nounderline abstract_t">Morrison TA, Wilcox I, Luo HY, et al. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis 2018; 69:1.</a></li><li><a class="nounderline abstract_t">Takase S, Hiroyama T, Shirai F, et al. A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression. Nat Commun 2023; 14:23.</a></li><li><a class="nounderline abstract_t">Lee YT, de Vasconcellos JF, Yuan J, et al. LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo. Blood 2013; 122:1034.</a></li><li><a class="nounderline abstract_t">Basak A, Munschauer M, Lareau CA, et al. Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation. Nat Genet 2020; 52:138.</a></li><li><a class="nounderline abstract_t">Masuda T, Wang X, Maeda M, et al. Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science 2016; 351:285.</a></li><li><a class="nounderline abstract_t">Shaikho EM, Habara AH, Alsultan A, et al. Variants of ZBTB7A (LRF) and its β-globin gene cluster binding motifs in sickle cell anemia. Blood Cells Mol Dis 2016; 59:49.</a></li><li><a class="nounderline abstract_t">Gardner K, Fulford T, Silver N, et al. g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. Blood Adv 2018; 2:235.</a></li><li><a class="nounderline abstract_t">Bauer DE, Kamran SC, Lessard S, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 2013; 342:253.</a></li><li><a class="nounderline abstract_t">Canver MC, Smith EC, Sher F, et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 2015; 527:192.</a></li><li><a class="nounderline abstract_t">Martyn GE, Wienert B, Kurita R, et al. A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site. Blood 2019; 133:852.</a></li><li><a class="nounderline abstract_t">Liu N, Xu S, Yao Q, et al. Transcription factor competition at the γ-globin promoters controls hemoglobin switching. Nat Genet 2021; 53:511.</a></li><li><a class="nounderline abstract_t">Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 2011; 334:993.</a></li><li><a class="nounderline abstract_t">Thein SL, Weatherall DJ. A non-deletion hereditary persistence of fetal hemoglobin (HPFH) determinant not linked to the beta-globin gene complex. Prog Clin Biol Res 1989; 316B:97.</a></li><li><a class="nounderline abstract_t">Menzel S, Jiang J, Silver N, et al. The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans. Blood 2007; 110:3624.</a></li><li><a class="nounderline abstract_t">Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A 2007; 104:11346.</a></li><li><a class="nounderline abstract_t">Farrell JJ, Sherva RM, Chen ZY, et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood 2011; 117:4935.</a></li><li><a class="nounderline abstract_t">Stadhouders R, Aktuna S, Thongjuea S, et al. HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. J Clin Invest 2014; 124:1699.</a></li><li><a class="nounderline abstract_t">Garner C, Mitchell J, Hatzis T, et al. Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am J Hum Genet 1998; 62:1468.</a></li><li><a class="nounderline abstract_t">Esteghamat F, Gillemans N, Bilic I, et al. Erythropoiesis and globin switching in compound Klf1::Bcl11a mutant mice. Blood 2013; 121:2553.</a></li><li><a class="nounderline abstract_t">Zhou D, Liu K, Sun CW, et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010; 42:742.</a></li><li><a class="nounderline abstract_t">Siatecka M, Bieker JJ. The multifunctional role of EKLF/KLF1 during erythropoiesis. Blood 2011; 118:2044.</a></li><li><a class="nounderline abstract_t">Norton LJ, Funnell APW, Burdach J, et al. KLF1 directly activates expression of the novel fetal globin repressor ZBTB7A/LRF in erythroid cells. Blood Adv 2017; 1:685.</a></li><li><a class="nounderline abstract_t">Yien YY, Bieker JJ. EKLF/KLF1, a tissue-restricted integrator of transcriptional control, chromatin remodeling, and lineage determination. Mol Cell Biol 2013; 33:4.</a></li><li><a class="nounderline abstract_t">Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010; 42:801.</a></li><li><a class="nounderline abstract_t">Liu D, Zhang X, Yu L, et al. KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia. Blood 2014; 124:803.</a></li><li><a class="nounderline abstract_t">Perkins A, Xu X, Higgs DR, et al. Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants. Blood 2016; 127:1856.</a></li><li><a class="nounderline abstract_t">Helias V, Saison C, Peyrard T, et al. Molecular analysis of the rare in(Lu) blood type: toward decoding the phenotypic outcome of haploinsufficiency for the transcription factor KLF1. Hum Mutat 2013; 34:221.</a></li><li><a class="nounderline abstract_t">Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 2010; 87:721.</a></li><li><a class="nounderline abstract_t">Jaffray JA, Mitchell WB, Gnanapragasam MN, et al. Erythroid transcription factor EKLF/KLF1 mutation causing congenital dyserythropoietic anemia type IV in a patient of Taiwanese origin: review of all reported cases and development of a clinical diagnostic paradigm. Blood Cells Mol Dis 2013; 51:71.</a></li><li><a class="nounderline abstract_t">Viprakasit V, Ekwattanakit S, Riolueang S, et al. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood 2014; 123:1586.</a></li><li><a class="nounderline abstract_t">Magor GW, Tallack MR, Gillinder KR, et al. KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome. Blood 2015; 125:2405.</a></li><li><a class="nounderline abstract_t">Satta S, Perseu L, Moi P, et al. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica 2011; 96:767.</a></li><li><a class="nounderline abstract_t">Gallienne AE, Dréau HM, Schuh A, et al. Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. Haematologica 2012; 97:340.</a></li><li><a class="nounderline abstract_t">Wienert B, Martyn GE, Kurita R, et al. KLF1 drives the expression of fetal hemoglobin in British HPFH. Blood 2017; 130:803.</a></li><li><a class="nounderline abstract_t">Ravi NS, Wienert B, Wyman SK, et al. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin. Elife 2022; 11.</a></li><li><a class="nounderline abstract_t">Bieker JJ. Putting a finger on the switch. Nat Genet 2010; 42:733.</a></li><li><a class="nounderline abstract_t">Galarneau G, Palmer CD, Sankaran VG, et al. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 2010; 42:1049.</a></li><li><a class="nounderline abstract_t">Huang P, Keller CA, Giardine B, et al. Comparative analysis of three-dimensional chromosomal architecture identifies a novel fetal hemoglobin regulatory element. Genes Dev 2017; 31:1704.</a></li><li><a class="nounderline abstract_t">Ma Y, Liu S, Gao J, et al. Genome-wide analysis of pseudogenes reveals HBBP1's human-specific essentiality in erythropoiesis and implication in β-thalassemia. Dev Cell 2021; 56:478.</a></li><li><a class="nounderline abstract_t">Xu J, Bauer DE, Kerenyi MA, et al. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci U S A 2013; 110:6518.</a></li><li><a class="nounderline abstract_t">Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 2010; 24:783.</a></li><li><a class="nounderline abstract_t">de Vasconcellos JF, Tumburu L, Byrnes C, et al. IGF2BP1 overexpression causes fetal-like hemoglobin expression patterns in cultured human adult erythroblasts. Proc Natl Acad Sci U S A 2017; 114:E5664.</a></li><li><a class="nounderline abstract_t">Wang Y, Li X, Ge J, et al. The methyltransferase PRMT1 regulates γ-globin translation. J Biol Chem 2021; 296:100417.</a></li><li><a class="nounderline abstract_t">Brendel C, Guda S, Renella R, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest 2016; 126:3868.</a></li><li><a class="nounderline abstract_t">Zeng J, Wu Y, Ren C, et al. Therapeutic base editing of human hematopoietic stem cells. Nat Med 2020; 26:535.</a></li><li class="breakAll">Wood WG. Hereditary persistence of fetal hemoglobin and δβ thalassemia. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. Vol 1, p.356.</li><li><a class="nounderline abstract_t">Neishabury M, Azarkeivan A, Oberkanins C, et al. Analyzing 5'HS3 and 5'HS4 LCR core regions and NF-E2 in Iranian thalassemia intermedia patients with normal or carrier status for beta-globin mutations. Blood Cells Mol Dis 2011; 46:201.</a></li><li><a class="nounderline abstract_t">Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood 2010; 115:1815.</a></li><li><a class="nounderline abstract_t">Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992; 80:816.</a></li><li><a class="nounderline abstract_t">Urio F, Nkya S, Rooks H, et al. F cell numbers are associated with an X-linked genetic polymorphism and correlate with haematological parameters in patients with sickle cell disease. Br J Haematol 2020; 191:888.</a></li><li><a class="nounderline abstract_t">de Vasconcellos JF, Lee YT, Byrnes C, et al. HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts. PLoS One 2016; 11:e0166928.</a></li><li><a class="nounderline abstract_t">Suzuki M, Yamamoto M, Engel JD. Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies. Mol Cell Biol 2014; 34:3560.</a></li><li><a class="nounderline abstract_t">Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med 2013; 19:291.</a></li><li><a class="nounderline abstract_t">van Dijk TB, Gillemans N, Stein C, et al. Friend of Prmt1, a novel chromatin target of protein arginine methyltransferases. Mol Cell Biol 2010; 30:260.</a></li><li><a class="nounderline abstract_t">Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A 2010; 107:12617.</a></li><li><a class="nounderline abstract_t">Lan X, Khandros E, Huang P, et al. The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells. Blood Adv 2019; 3:1586.</a></li><li><a class="nounderline abstract_t">Dai Y, Chen T, Ijaz H, et al. SIRT1 activates the expression of fetal hemoglobin genes. Am J Hematol 2017; 92:1177.</a></li><li><a class="nounderline abstract_t">Gudmundsdottir B, Gudmundsson KO, Klarmann KD, et al. POGZ Is Required for Silencing Mouse Embryonic β-like Hemoglobin and Human Fetal Hemoglobin Expression. Cell Rep 2018; 23:3236.</a></li><li><a class="nounderline abstract_t">Zhang Y, Paikari A, Sumazin P, et al. Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells. Blood 2018; 132:321.</a></li><li><a class="nounderline abstract_t">Hahn CK, Lowrey CH. Induction of fetal hemoglobin through enhanced translation efficiency of γ-globin mRNA. Blood 2014; 124:2730.</a></li><li><a class="nounderline abstract_t">Jiang Z, Luo HY, Farrell JJ, et al. A variant Sp1 (R218Q) transcription factor might enhance HbF expression in β0 -thalassaemia homozygotes. Br J Haematol 2018; 180:755.</a></li><li><a class="nounderline abstract_t">Lan X, Ren R, Feng R, et al. ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression. Mol Cell 2021; 81:239.</a></li><li><a class="nounderline abstract_t">Sher F, Hossain M, Seruggia D, et al. Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis. Nat Genet 2019; 51:1149.</a></li><li><a class="nounderline abstract_t">Vinjamur DS, Yao Q, Cole MA, et al. ZNF410 represses fetal globin by singular control of CHD4. Nat Genet 2021; 53:719.</a></li><li><a class="nounderline abstract_t">Vathipadiekal V, Farrell JJ, Wang S, et al. A candidate transacting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia. Am J Hematol 2016; 91:1118.</a></li><li><a class="nounderline abstract_t">Al-Ali ZA, Fallatah RK, Aljaffer EA, et al. ANTXR1 Intronic Variants Are Associated with Fetal Hemoglobin in the Arab-Indian Haplotype of Sickle Cell Disease. Acta Haematol 2018; 140:55.</a></li><li><a class="nounderline abstract_t">Grevet JD, Lan X, Hamagami N, et al. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. Science 2018; 361:285.</a></li><li><a class="nounderline abstract_t">Huang P, Peslak SA, Lan X, et al. The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression. Blood 2020; 135:2121.</a></li><li><a class="nounderline abstract_t">Yu X, Azzo A, Bilinovich SM, et al. Disruption of the MBD2-NuRD complex but not MBD3-NuRD induces high level HbF expression in human adult erythroid cells. Haematologica 2019; 104:2361.</a></li><li><a class="nounderline abstract_t">Bao X, Zhang X, Wang L, et al. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia. Am J Hum Genet 2021; 108:709.</a></li><li><a class="nounderline abstract_t">Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood 2012; 120:2945.</a></li><li><a class="nounderline abstract_t">Perrine SP. Hemoglobin F: new targets, new path. Blood 2006; 108:783.</a></li><li><a class="nounderline abstract_t">Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997; 89:1078.</a></li><li><a class="nounderline abstract_t">Steinberg MH, Chui DH, Dover GJ, et al. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood 2014; 123:481.</a></li><li><a class="nounderline abstract_t">Hebert N, Rakotoson MG, Bodivit G, et al. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. Am J Hematol 2020; 95:1235.</a></li><li><a class="nounderline abstract_t">Dover GJ, Boyer SH. Quantitation of hemoglobins within individual red cells: asynchronous biosynthesis of fetal and adult hemoglobin during erythroid maturation in normal subjects. Blood 1980; 56:1082.</a></li><li><a class="nounderline abstract_t">Dover GJ, Boyer SH, Charache S, Heintzelman K. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med 1978; 299:1428.</a></li><li><a class="nounderline abstract_t">Franco RS, Lohmann J, Silberstein EB, et al. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J Clin Invest 1998; 101:2730.</a></li><li><a class="nounderline abstract_t">Dover GJ, Boyer SH, Bell WR. Microscopic method for assaying F cell production: illustrative changes during infancy and in aplastic anemia. Blood 1978; 52:664.</a></li><li><a class="nounderline abstract_t">Thein SL, Craig JE. Genetics of Hb F/F cell variance in adults and heterocellular hereditary persistence of fetal hemoglobin. Hemoglobin 1998; 22:401.</a></li><li><a class="nounderline abstract_t">Creary LE, McKenzie CA, Menzel S, et al. Ethnic differences in F cell levels in Jamaica: a potential tool for identifying new genetic loci controlling fetal haemoglobin. Br J Haematol 2009; 144:954.</a></li><li><a class="nounderline abstract_t">Zago MA, Wood WG, Clegg JB, et al. Genetic control of F cells in human adults. Blood 1979; 53:977.</a></li><li class="breakAll">Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 4th ed, Blackwell Science, Oxford 2001.</li><li><a class="nounderline abstract_t">Ho PJ, Hall GW, Luo LY, et al. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol 1998; 100:70.</a></li><li><a class="nounderline abstract_t">Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010; 5:11.</a></li><li><a class="nounderline abstract_t">Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med 2013; 3:a011700.</a></li><li><a class="nounderline abstract_t">Craig JE, Kelly SJ, Barnetson R, Thein SL. Molecular characterization of a novel 10.3 kb deletion causing beta-thalassaemia with unusually high Hb A2. Br J Haematol 1992; 82:735.</a></li><li><a class="nounderline abstract_t">Giardine B, Borg J, Higgs DR, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet 2011; 43:295.</a></li><li><a class="nounderline abstract_t">Martyn GE, Wienert B, Yang L, et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. Nat Genet 2018; 50:498.</a></li><li><a class="nounderline abstract_t">Gilman JG, Mishima N, Wen XJ, et al. Distal CCAAT box deletion in the A gamma globin gene of two black adolescents with elevated fetal A gamma globin. Nucleic Acids Res 1988; 16:10635.</a></li><li><a class="nounderline abstract_t">Traxler EA, Yao Y, Wang YD, et al. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med 2016; 22:987.</a></li><li><a class="nounderline abstract_t">Shimasaki S, Iuchi I. Diversity of human gamma-globin gene loci including a quadruplicated arrangement. Blood 1986; 67:784.</a></li><li><a class="nounderline abstract_t">Thein SL, Hill FG, Weatherall DJ. Haematological phenotype of the triplicated gamma-globin gene arrangement. Br J Haematol 1984; 57:349.</a></li><li class="breakAll">http://globin.cse.psu.edu (Accessed on February 11, 2014).</li><li><a class="nounderline abstract_t">Chakalova L, Osborne CS, Dai YF, et al. The Corfu deltabeta thalassemia deletion disrupts gamma-globin gene silencing and reveals post-transcriptional regulation of HbF expression. Blood 2005; 105:2154.</a></li><li><a class="nounderline abstract_t">Galanello R, Melis MA, Podda A, et al. Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome. Blood 1990; 75:1747.</a></li><li><a class="nounderline abstract_t">Kulozik AE, Yarwood N, Jones RW. The Corfu delta beta zero thalassemia: a small deletion acts at a distance to selectively abolish beta globin gene expression. Blood 1988; 71:457.</a></li><li><a class="nounderline abstract_t">Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. N Engl J Med 2011; 365:807.</a></li><li><a class="nounderline abstract_t">Feingold EA, Forget BG. The breakpoint of a large deletion causing hereditary persistence of fetal hemoglobin occurs within an erythroid DNA domain remote from the beta-globin gene cluster. Blood 1989; 74:2178.</a></li><li><a class="nounderline abstract_t">Tuan D, Feingold E, Newman M, et al. Different 3' end points of deletions causing delta beta-thalassemia and hereditary persistence of fetal hemoglobin: implications for the control of gamma-globin gene expression in man. Proc Natl Acad Sci U S A 1983; 80:6937.</a></li><li><a class="nounderline abstract_t">Steinberg MH. Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Cancio MI, Aygun B, Chui DHK, et al. The clinical severity of hemoglobin S/Black (A γδβ)0 -thalassemia. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood 2017; 129:2719.</a></li><li><a class="nounderline abstract_t">Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med 2006; 41:1557.</a></li><li><a class="nounderline abstract_t">Deonikar P, Kavdia M. Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis. J Appl Physiol (1985) 2012; 112:1383.</a></li><li><a class="nounderline abstract_t">Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21:37.</a></li><li><a class="nounderline abstract_t">Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74:1403.</a></li><li><a class="nounderline abstract_t">Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133:570.</a></li><li><a class="nounderline abstract_t">Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.</a></li><li><a class="nounderline abstract_t">Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984; 63:921.</a></li><li><a class="nounderline abstract_t">Brousse V, El Hoss S, Bouazza N, et al. Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study. Am J Hematol 2018; 93:1411.</a></li><li><a class="nounderline abstract_t">Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med 2021; 384:252.</a></li><li><a class="nounderline abstract_t">Sebastiani P, Steinberg MH. Fetal hemoglobin per erythrocyte (HbF/F-cell) after gene therapy for sickle cell anemia. Am J Hematol 2023; 98:E32.</a></li><li><a class="nounderline abstract_t">Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood 1994; 84:3182.</a></li><li><a class="nounderline abstract_t">Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118:19.</a></li><li><a class="nounderline abstract_t">Dover GJ, Boyer SH. Hemoglobin determinations in single cells: Comparison of different techniques. Prog Clin Biol Res 1981; 60:115.</a></li><li><a class="nounderline abstract_t">Alsultan A, Solovieff N, Aleem A, et al. Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. Am J Hematol 2011; 86:612.</a></li><li><a class="nounderline abstract_t">Al-Ali AK, Alsulaiman A, Alzahrani AJ, et al. Prevalence and Diversity of Haplotypes of Sickle Cell Disease in the Eastern Province of Saudi Arabia. Hemoglobin 2020; 44:78.</a></li><li><a class="nounderline abstract_t">Perrine RP, Brown MJ, Clegg JB, et al. Benign sickle-cell anaemia. Lancet 1972; 2:1163.</a></li><li><a class="nounderline abstract_t">Alsultan A, Alabdulaali MK, Griffin PJ, et al. Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign. Br J Haematol 2014; 164:597.</a></li><li><a class="nounderline abstract_t">Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis 2008; 41:255.</a></li><li><a class="nounderline abstract_t">Bae HT, Baldwin CT, Sebastiani P, et al. Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans. Blood 2012; 120:1961.</a></li><li><a class="nounderline abstract_t">Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A 2008; 105:11869.</a></li><li><a class="nounderline abstract_t">Makani J, Menzel S, Nkya S, et al. Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood 2011; 117:1390.</a></li><li><a class="nounderline abstract_t">Labie D, Pagnier J, Lapoumeroulie C, et al. Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci U S A 1985; 82:2111.</a></li><li><a class="nounderline abstract_t">Ngo D, Bae H, Steinberg MH, et al. Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype. Blood Cells Mol Dis 2013; 51:22.</a></li><li><a class="nounderline abstract_t">Mtatiro SN, Singh T, Rooks H, et al. Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania. PLoS One 2014; 9:e111464.</a></li><li><a class="nounderline abstract_t">Bhanushali AA, Patra PK, Nair D, et al. Genetic variant in the BCL11A (rs1427407), but not HBS1-MYB (rs6934903) loci associate with fetal hemoglobin levels in Indian sickle cell disease patients. Blood Cells Mol Dis 2015; 54:4.</a></li><li><a class="nounderline abstract_t">Al-Ali AK, Alsulaiman A, Alfarhan M, et al. Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features. Am J Hematol 2021; 96:E117.</a></li><li><a class="nounderline abstract_t">Pule GD, Ngo Bitoungui VJ, Chetcha Chemegni B, et al. Association between Variants at BCL11A Erythroid-Specific Enhancer and Fetal Hemoglobin Levels among Sickle Cell Disease Patients in Cameroon: Implications for Future Therapeutic Interventions. OMICS 2015; 19:627.</a></li><li><a class="nounderline abstract_t">Bitoungui VJ, Ngogang J, Wonkam A. Polymorphism at BCL11A compared to HBS1L-MYB loci explains less of the variance in HbF in patients with sickle cell disease in Cameroon. Blood Cells Mol Dis 2015; 54:268.</a></li><li><a class="nounderline abstract_t">Adekile AD. Historical and anthropological correlates of beta S haplotypes and alpha- and beta-thalassemia alleles in the Arabian Peninsula. Hemoglobin 1997; 21:281.</a></li><li><a class="nounderline abstract_t">Lapouméroulie C, Dunda O, Ducrocq R, et al. A novel sickle cell mutation of yet another origin in Africa: the Cameroon type. Hum Genet 1992; 89:333.</a></li><li class="breakAll">Nagel RL. Origins and dispersion of the sickle g. In: Cell Disease: Basic Principles and Clinical Practice, mbury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. Vol 1, p.353.</li><li><a class="nounderline abstract_t">Green NS, Fabry ME, Kaptue-Noche L, Nagel RL. Senegal haplotype is associated with higher HbF than Benin and Cameroon haplotypes in African children with sickle cell anemia. Am J Hematol 1993; 44:145.</a></li><li><a class="nounderline abstract_t">Nagel RL, Rao SK, Dunda-Belkhodja O, et al. The hematologic characteristics of sickle cell anemia bearing the Bantu haplotype: the relationship between G gamma and HbF level. Blood 1987; 69:1026.</a></li><li><a class="nounderline abstract_t">Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N Engl J Med 1985; 312:880.</a></li><li><a class="nounderline abstract_t">Padmos MA, Roberts GT, Sackey K, et al. Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Br J Haematol 1991; 79:93.</a></li><li><a class="nounderline abstract_t">Pembrey ME, Wood WG, Weatherall DJ, Perrine RP. Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia. Br J Haematol 1978; 40:415.</a></li><li><a class="nounderline abstract_t">el-Hazmi MA. Heterogeneity and variation of clinical and haematological expression of haemoglobin S in Saudi Arabs. Acta Haematol 1992; 88:67.</a></li><li><a class="nounderline abstract_t">Kulozik AE, Bail S, Kar BC, et al. Sickle cell-beta+ thalassaemia in Orissa State, India. Br J Haematol 1991; 77:215.</a></li><li><a class="nounderline abstract_t">Kulozik AE, Kar BC, Satapathy RK, et al. Fetal hemoglobin levels and beta (s) globin haplotypes in an Indian populations with sickle cell disease. Blood 1987; 69:1742.</a></li><li><a class="nounderline abstract_t">Kulozik AE, Wainscoat JS, Serjeant GR, et al. Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet 1986; 39:239.</a></li><li><a class="nounderline abstract_t">Ngo DA, Aygun B, Akinsheye I, et al. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol 2012; 156:259.</a></li><li><a class="nounderline abstract_t">Bard H. Postnatal fetal and adult hemoglobin synthesis in early preterm newborn infants. J Clin Invest 1973; 52:1789.</a></li><li><a class="nounderline abstract_t">Bard H, Prosmanne J. Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. Pediatrics 1985; 75:1143.</a></li><li><a class="nounderline abstract_t">Perrine SP, Greene MF, Faller DV. Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med 1985; 312:334.</a></li><li><a class="nounderline abstract_t">Perrine SP, Rudolph A, Faller DV, et al. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci U S A 1988; 85:8540.</a></li><li><a class="nounderline abstract_t">Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993; 328:81.</a></li><li><a class="nounderline abstract_t">Kutlar A, Ataga K, Reid M, et al. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol 2012; 87:1017.</a></li><li><a class="nounderline abstract_t">Fucharoen S, Inati A, Siritanaratku N, et al. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. Br J Haematol 2013; 161:587.</a></li><li><a class="nounderline abstract_t">HUEHNS ER, HECHT F, KEIL JV, MOTULSKY AG. DEVELOPMENTAL HEMOGLOBIN ANOMALIES IN A CHROMOSOMAL TRIPLICATION: D1 TRISOMY SYNDROME. Proc Natl Acad Sci U S A 1964; 51:89.</a></li><li><a class="nounderline abstract_t">Sankaran VG, Sapp MV. Persistence of fetal hemoglobin expression in an older child with trisomy 13. J Pediatr 2012; 160:352.</a></li><li><a class="nounderline abstract_t">Sankaran VG, Menne TF, Šćepanović D, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci U S A 2011; 108:1519.</a></li><li><a class="nounderline abstract_t">Xiang J, Wu DC, Chen Y, Paulson RF. In vitro culture of stress erythroid progenitors identifies distinct progenitor populations and analogous human progenitors. Blood 2015; 125:1803.</a></li><li><a class="nounderline abstract_t">Sheridan BL, Weatherall DJ, Clegg JB, et al. The patterns of fetal haemoglobin production in leukaemia. Br J Haematol 1976; 32:487.</a></li><li><a class="nounderline abstract_t">Alter BP, Rappeport JM, Huisman TH, et al. Fetal erythropoiesis following bone marrow transplantation. Blood 1976; 48:843.</a></li><li><a class="nounderline abstract_t">Dover GJ, Boyer SH, Zinkham WH. Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes. J Clin Invest 1979; 63:173.</a></li><li><a class="nounderline abstract_t">Papayannopoulou T, Vichinsky E, Stamatoyannopoulos G. Fetal Hb production during acute erythroid expansion. I. Observations in patients with transient erythroblastopenia and post-phlebotomy. Br J Haematol 1980; 44:535.</a></li><li><a class="nounderline abstract_t">Ibrahim M, Qari MH, Sait W, Abulela M. Pattern of HB F level rise during normal pregnancies. Hemoglobin 2009; 33:534.</a></li><li><a class="nounderline abstract_t">Popat N, Wood WG, Weatherall DJ, Turnbull AC. Pattern of maternal F-cell production during pregnancy. Lancet 1977; 2:377.</a></li><li><a class="nounderline abstract_t">Alter BP. Fetal erythropoiesis in stress hematopoiesis. Exp Hematol 1979; 7 Suppl 5:200.</a></li><li><a class="nounderline abstract_t">Alter BP, Rosenberg PS, Day T, et al. Genetic regulation of fetal haemoglobin in inherited bone marrow failure syndromes. Br J Haematol 2013; 162:542.</a></li><li><a class="nounderline abstract_t">Weatherall DJ, Clegg JB, Wood WG, et al. Foetal erythropoiesis in human leukaemia. Nature 1975; 257:710.</a></li><li><a class="nounderline abstract_t">Weatherall DJ, Edwards JA, Donohoe WT. Haemoglobin and red cell enzyme changes in juvenile myeloid leukaemia. Br Med J 1968; 1:679.</a></li><li><a class="nounderline abstract_t">Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89:3534.</a></li><li><a class="nounderline abstract_t">Papayannopoulou T, Nakamoto B, Anagnou NP, et al. Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia. Blood 1991; 77:2569.</a></li><li><a class="nounderline abstract_t">Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995; 85:1742.</a></li><li><a class="nounderline abstract_t">Craig JE, Sampietro M, Oscier DG, et al. Myelodysplastic syndrome with karyotype abnormality is associated with elevated F-cell production. Br J Haematol 1996; 93:601.</a></li><li><a class="nounderline abstract_t">Lübbert M, Ihorst G, Sander PN, et al. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine). Br J Haematol 2017; 176:609.</a></li><li><a class="nounderline abstract_t">Igbineweka NE, Pilarski A, Rooks H, et al. Common Genetic Variants of Fetal Hemoglobin Modify Hematological Phenotypes in MDS/MPN/Myeloma Patients Receiving Cytotoxic Drugs. Ann Hematol Oncol 2022; 9:1403.</a></li><li><a class="nounderline abstract_t">Krauss JS, Rodriguez AR, Milner PF. Erythroleukemia with high fetal hemoglobin after therapy for ovarian carcinoma. Am J Clin Pathol 1981; 76:721.</a></li><li><a class="nounderline abstract_t">Chudwin DS, Rucknagel DL, Scholnik AP, et al. Fetal hemoglobin and alpha-fetoprotein in various malignancies. Acta Haematol 1977; 58:288.</a></li><li><a class="nounderline abstract_t">Stewart C. The occurrence of foetal haemoglobin in a patient with hepatoma. Med J Aust 1971; 2:664.</a></li><li><a class="nounderline abstract_t">Nyman M, Skölling R, Steiner H. Acquired macrocytic anemia and hemoglobinopathy--a paraneoplastic manifestation? Am J Med 1970; 48:792.</a></li><li class="breakAll">Wood WG. Increased HbF in adult life. In: Baillière's Clinical Haematology: International Practice and Research, Higgs DR, Weatherall DJ (Eds), Baillière Tindall, W.B. Saunders, London 1993. Vol 1, p.177.</li><li><a class="nounderline abstract_t">Creary SE, Pyle-Eilola AL, Varga E, et al. Method-dependent Discrepancies in Fetal Hemoglobin Quantification in Patients With Hemoglobin S. J Pediatr Hematol Oncol 2016; 38:402.</a></li><li><a class="nounderline abstract_t">Leonova JYe, Kazanetz EG, Smetanina NS, et al. Variability in the fetal hemoglobin level of the normal adult. Am J Hematol 1996; 53:59.</a></li><li><a class="nounderline abstract_t">Dulmovits BM, Appiah-Kubi AO, Papoin J, et al. Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood 2016; 127:1481.</a></li><li><a class="nounderline abstract_t">Hahn CK, Lowrey CH. Eukaryotic initiation factor 2α phosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanism. Blood 2013; 122:477.</a></li><li><a class="nounderline abstract_t">Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 2005; 105:1807.</a></li><li><a class="nounderline abstract_t">Habara AH, Shaikho EM, Steinberg MH. Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents. Am J Hematol 2017; 92:1233.</a></li><li><a class="nounderline abstract_t">Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood 2020; 136:2392.</a></li><li><a class="nounderline abstract_t">Esrick EB, Lehmann LE, Biffi A, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med 2021; 384:205.</a></li><li><a class="nounderline abstract_t">Kanter J, Walters MC, Krishnamurti L, et al. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. N Engl J Med 2022; 386:617.</a></li></ol></div><div id="topicVersionRevision">Topic 90749 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23209182" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evolution of hemoglobin and its genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7438203" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Human fetal G gamma- and A gamma-globin genes: complete nucleotide sequences suggest that DNA can be exchanged between these duplicated genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2337675" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Characterization of two types of fetal hemoglobin: alpha 2G gamma 2 and alpha 2A gamma 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474145" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changes in the G gamma- and A gamma-globin mRNA components of fetal hemoglobin during human development</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/939551" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Significance of a new type of human fetal hemoglobin carrying a replacement isoleucine replaced by threonine at position 75 )E 19) of the gamma chain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/881729" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Structure of human foetal deoxyhaemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3571243" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The kinetics of assembly of normal and variant human oxyhemoglobins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13987081" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hemoglobin F1, an acetyl-containing hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/284392" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13800165" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Estimation of small percentages of foetal haemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231030" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Detection of fetomaternal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746793" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Transgenic mice expressing human fetal globin are protected from malaria by a novel mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742119" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : N-terminal contributions of the gamma-subunit of fetal hemoglobin to its tetramer strength: remote effects at subunit contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11742119" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : N-terminal contributions of the gamma-subunit of fetal hemoglobin to its tetramer strength: remote effects at subunit contacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21532754" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A role for fetal hemoglobin and maternal immune IgG in infant resistance to Plasmodium falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31311778" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fetal hemoglobin does not inhibit Plasmodium falciparum growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607722" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic influences on F cells and other hematologic variables: a twin heritability study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344402" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Discovering the genetics underlying foetal haemoglobin production in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808799" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Control of fetal hemoglobin: new insights emerging from genomics and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29193029" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31322165" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gene therapy of hemoglobinopathies: progress and future challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143582" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An international effort to cure a global health problem: A report on the 19th Hemoglobin Switching Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30478714" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30355263" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Emerging Genetic Therapy for Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27353686" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30287096" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Wake-up Sleepy Gene: Reactivating Fetal Globin forβ-Hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30504332" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form ofα-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29227829" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36635268" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798711" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31959994" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26816381" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27282567" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Variants of ZBTB7A (LRF) and itsβ-globin gene cluster binding motifs in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437638" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : g(HbF): a genetic model of fetal hemoglobin in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24115442" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375006" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617196" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33649594" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transcription factor competition at theγ-globin promoters controls hemoglobin switching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998251" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2482508" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A non-deletion hereditary persistence of fetal hemoglobin (HPFH) determinant not linked to the beta-globin gene complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712044" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17592125" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385855" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24614105" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585587" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361909" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Erythropoiesis and globin switching in compound Klf1::Bcl11a mutant mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676097" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21613252" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The multifunctional role of EKLF/KLF1 during erythropoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296711" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : KLF1 directly activates expression of the novel fetal globin repressor ZBTB7A/LRF in erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090966" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : EKLF/KLF1, a tissue-restricted integrator of transcriptional control, chromatin remodeling, and lineage determination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676099" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829204" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity ofβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903544" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23125034" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Molecular analysis of the rare in(Lu) blood type: toward decoding the phenotypic outcome of haploinsufficiency for the transcription factor KLF1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055716" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23522491" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Erythroid transcription factor EKLF/KLF1 mutation causing congenital dyserythropoietic anemia type IV in a patient of Taiwanese origin: review of all reported cases and development of a clinical diagnostic paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24443441" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25724378" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : KLF1-null neonates display hydrops fetalis and a deranged erythroid transcriptome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21273267" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22102705" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28659276" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : KLF1 drives the expression of fetal hemoglobin in British HPFH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35147495" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20802474" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Putting a finger on the switch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057501" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28916711" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Comparative analysis of three-dimensional chromosomal architecture identifies a novel fetal hemoglobin regulatory element.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476555" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Genome-wide analysis of pseudogenes reveals HBBP1's human-specific essentiality in erythropoiesis and implication inβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23576758" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395365" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28652347" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : IGF2BP1 overexpression causes fetal-like hemoglobin expression patterns in cultured human adult erythroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33587951" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The methyltransferase PRMT1 regulatesγ-globin translation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27599293" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32284612" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Therapeutic base editing of human hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32284612" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Therapeutic base editing of human hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21232998" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Analyzing 5'HS3 and 5'HS4 LCR core regions and NF-E2 in Iranian thalassemia intermedia patients with normal or carrier status for beta-globin mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20018918" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1379090" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073380" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : F cell numbers are associated with an X-linked genetic polymorphism and correlate with haematological parameters in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861570" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25022757" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Fetal globin gene repressors as drug targets for molecular therapies to treat theβ-globinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23416702" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858291" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Friend of Prmt1, a novel chromatin target of protein arginine methyltransferases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20616024" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31126914" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28776729" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : SIRT1 activates the expression of fetal hemoglobin genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898395" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : POGZ Is Required for Silencing Mouse Embryonicβ-like Hemoglobin and Human Fetal Hemoglobin Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29884740" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170120" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Induction of fetal hemoglobin through enhanced translation efficiency ofγ-globin mRNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240767" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A variant Sp1 (R218Q) transcription factor might enhance HbF expression inβ0 -thalassaemia homozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301730" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31253978" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33859416" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : ZNF410 represses fetal globin by singular control of CHD4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27501013" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A candidate transacting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30114697" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : ANTXR1 Intronic Variants Are Associated with Fetal Hemoglobin in the Arab-Indian Haplotype of Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30026227" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299090" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31004025" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Disruption of the MBD2-NuRD complex but not MBD3-NuRD induces high level HbF expression in human adult erythroid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735615" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Epigenetic inactivation of ERF reactivatesγ-globin expression inβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22904296" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Reawakening fetal hemoglobin: prospects for new therapies for theβ-globin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hemoglobin F: new targets, new path</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028341" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24222332" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Fetal hemoglobin in sickle cell anemia: a glass half full?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32681733" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6159933" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Quantitation of hemoglobins within individual red cells: asynchronous biosynthesis of fetal and adult hemoglobin during erythroid maturation in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/101847" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Individual variation in the production and survival of F cells in sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637707" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/99196" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Microscopic method for assaying F cell production: illustrative changes during infancy and in aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9859924" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Genetics of Hb F/F cell variance in adults and heterocellular hereditary persistence of fetal hemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120354" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Ethnic differences in F cell levels in Jamaica: a potential tool for identifying new genetic loci controlling fetal haemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/373818" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Genetic control of F cells in human adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/373818" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Genetic control of F cells in human adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9450794" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492708" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Beta-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23637309" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The molecular basis ofβ-thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1482661" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Molecular characterization of a novel 10.3 kb deletion causing beta-thalassaemia with unusually high Hb A2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21423179" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610478" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2462713" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Distal CCAAT box deletion in the A gamma globin gene of two black adolescents with elevated fetal A gamma globin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27525524" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A genome-editing strategy to treatβ-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3947746" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Diversity of human gamma-globin gene loci including a quadruplicated arrangement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6733050" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Haematological phenotype of the triplicated gamma-globin gene arrangement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6733050" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Haematological phenotype of the triplicated gamma-globin gene arrangement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536151" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The Corfu deltabeta thalassemia deletion disrupts gamma-globin gene silencing and reveals post-transcriptional regulation of HbF expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691668" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827815" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The Corfu delta beta zero thalassemia: a small deletion acts at a distance to selectively abolish beta globin gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21879898" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A functional element necessary for fetal hemoglobin silencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2478223" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The breakpoint of a large deletion causing hereditary persistence of fetal hemoglobin occurs within an erythroid DNA domain remote from the beta-globin gene cluster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6196781" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Different 3' end points of deletions causing delta beta-thalassemia and hereditary persistence of fetal hemoglobin: implications for the control of gamma-globin gene expression in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33238542" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453928" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The clinical severity of hemoglobin S/Black (Aγδβ)0 -thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385699" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Treating sickle cell disease by targeting HbS polymerization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045924" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223452" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084951" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2475188" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Leg ulcers in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681647" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993409" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Mortality in sickle cell disease. Life expectancy and risk factors for early death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6200161" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30132969" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283989" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : CRISPR-Cas9 Gene Editing for Sickle Cell Disease andβ-Thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36420999" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Fetal hemoglobin per erythrocyte (HbF/F-cell) after gene therapy for sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524767" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21490337" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Fetal hemoglobin in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6169088" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hemoglobin determinations in single cells: Comparison of different techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21630302" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32448003" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Prevalence and Diversity of Haplotypes of Sickle Cell Disease in the Eastern Province of Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4117591" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Benign sickle-cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24224700" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691915" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22936743" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18667698" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068433" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2580306" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465615" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25372704" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Genome wide association study of fetal hemoglobin in sickle cell anemia in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25457385" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Genetic variant in the BCL11A (rs1427407), but not HBS1-MYB (rs6934903) loci associate with fetal hemoglobin levels in Indian sickle cell disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33460474" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393293" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Association between Variants at BCL11A Erythroid-Specific Enhancer and Fetal Hemoglobin Levels among Sickle Cell Disease Patients in Cameroon: Implications for Future Therapeutic Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488618" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Polymorphism at BCL11A compared to HBS1L-MYB loci explains less of the variance in HbF in patients with sickle cell disease in Cameroon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9140724" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Historical and anthropological correlates of beta S haplotypes and alpha- and beta-thalassemia alleles in the Arabian Peninsula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376298" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : A novel sickle cell mutation of yet another origin in Africa: the Cameroon type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376298" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : A novel sickle cell mutation of yet another origin in Africa: the Cameroon type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7505527" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Senegal haplotype is associated with higher HbF than Benin and Cameroon haplotypes in African children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2435339" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : The hematologic characteristics of sickle cell anemia bearing the Bantu haplotype: the relationship between G gamma and HbF level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2579336" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1716963" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Two different forms of homozygous sickle cell disease occur in Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/749927" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Fetal haemoglobin production and the sickle gene in the oases of Eastern Saudi Arabia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1281601" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Heterogeneity and variation of clinical and haematological expression of haemoglobin S in Saudi Arabs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2004023" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Sickle cell-beta+ thalassaemia in Orissa State, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437982" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Fetal hemoglobin levels and beta (s) globin haplotypes in an Indian populations with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752087" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017641" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4719660" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Postnatal fetal and adult hemoglobin synthesis in early preterm newborn infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4000790" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2578609" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Delay in the fetal globin switch in infants of diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2460870" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677966" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22887019" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530969" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, inβ-thalassaemia intermedia and HbE/β-thalassaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14104609" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : DEVELOPMENTAL HEMOGLOBIN ANOMALIES IN A CHROMOSOMAL TRIPLICATION: D1 TRISOMY SYNDROME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21885064" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Persistence of fetal hemoglobin expression in an older child with trisomy 13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205891" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25608563" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : In vitro culture of stress erythroid progenitors identifies distinct progenitor populations and analogous human progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/816370" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : The patterns of fetal haemoglobin production in leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/793650" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Fetal erythropoiesis following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/429549" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6155136" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Fetal Hb production during acute erythroid expansion. I. Observations in patients with transient erythroblastopenia and post-phlebotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958203" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Pattern of HB F level rise during normal pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/70589" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Pattern of maternal F-cell production during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/95616" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Fetal erythropoiesis in stress hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23713742" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Genetic regulation of fetal haemoglobin in inherited bone marrow failure syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/810726" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Foetal erythropoiesis in human leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4966603" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Haemoglobin and red cell enzyme changes in juvenile myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9160658" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2043763" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Expression of embryonic globins by erythroid cells in juvenile chronic myelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7703482" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652380" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Myelodysplastic syndrome with karyotype abnormality is associated with elevated F-cell production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27905102" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Common Genetic Variants of Fetal Hemoglobin Modify Hematological Phenotypes in MDS/MPN/Myeloma Patients Receiving Cytotoxic Drugs</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6170223" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Erythroleukemia with high fetal hemoglobin after therapy for ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/74180" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Fetal hemoglobin and alpha-fetoprotein in various malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4329910" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : The occurrence of foetal haemoglobin in a patient with hepatoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5420567" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Acquired macrocytic anemia and hemoglobinopathy--a paraneoplastic manifestation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5420567" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Acquired macrocytic anemia and hemoglobinopathy--a paraneoplastic manifestation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164532" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Method-dependent Discrepancies in Fetal Hemoglobin Quantification in Patients With Hemoglobin S.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8892728" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Variability in the fetal hemoglobin level of the normal adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679864" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Pomalidomide reversesγ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690448" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Eukaryotic initiation factor 2αphosphorylation mediates fetal hemoglobin induction through a post-transcriptional mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15479724" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Butyrate increases the efficiency of translation of gamma-globin mRNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28736939" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32808012" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Fetal hemoglobin in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283990" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34898139" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
